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ABSTRACT 
Cancer is a leading cause of death worldwide. This disease is nowadays considered to be caused by 
both genetic and epigenetic alterations, which through activating oncogenes and/or inactivating 
tumor-suppression genes, leads to an uncontrolled cell growth and division. Although the 
involvement and function of genetic changes in cancer are well established, the field of cancer 
epigenetics is still relatively new and there is yet a lot to be learned about the involvement and 
function of epigenetic changes in cancer. One of the more thoroughly studied epigenetic changes in 
cancer is that of excessive DNA methylation at promoter regions, which has been linked to the 
silencing of for example tumor-suppressor genes. Therefore, in order to contribute to the 
understanding and elucidation of how genes may be epigenetically regulated in cancer, I investigated 
the recently accepted tumor-suppressor, NDRG2, which has been shown to be down-regulated for 
many cancers and to be subjected to excessive DNA methylation at the promoter region, using the 
cancer cell lines HCT116 and SW480. 
The NDRG2 expression was analyzed by Quantitative Real Time Reverse Transcriptase Polymerase 
Chain Reaction (qRT-PCR) and experiments showed that NDRG2 levels were significantly down-
regulated in both cancer cell lines. Further, the NDRG2 protein level was analyzed by western blotting 
for the HCT116 cells and results showed that NDRG2 was also down-regulated at protein level in 
this cell line. Additionally, the NDRG2 promoter was examined by Methylation specific Polymerase 
Chain Reaction (MSP) and sequencing, which showed that the previously observed NDRG2 down-
regulation also correlated with an excessive DNA methylation at the promoter region in both cancer 
cell lines. Therefore in order to further investigate the correlation, the HCT116 cells were treated with 
the demethylating agent, 5-azacytidine, and analyzed by qRT-PCR. This revealed that the cells treated 
with 5-azacytidine had a significantly increased NDRG2 expression, when compared to untreated 
cells.  
The promoter of NDRG2 was also investigated by Chromatin Immunoprecipitation (ChIP) for the 
binding of MYC and MeCP2, and the result was analyzed by Quantitative Real Time Polymerase 
Chain Reaction (qPCR), to see if these proteins contributed to the down-regulation of NDRG2 
expression. The results showed that MYC was capable of binding to the NDRG2 promoter, but that 
the MeCP2 was not. 
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In conclusion, these results strongly indicate that the down-regulation of NDRG2 observed for both 
cancer cell lines and the down-regulation of NDRG2 protein shown for the HCT116 cells, is caused 
by the methylation of the NDRG2 promoter region and this notion is in fact supported by the 5-
azacytidine being capable of restoring the NDRG2 expression in the HCT116 cells. In addition, it 
seems like MYC is also involved in regulating NDRG2, but this relation will have to be further 
investigated. 
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ABSTRAKT 
Cancer er en af de hyppigest forekommende dødsårsager på verdensplan. Idag ansees denne sygdom 
som værende både forårsaget af genetiske og epigenetiske ændringer, som ved onkogen aktivering 
og/eller inaktivering af tumor-suppressor gener, fører til ukontrollerbar celle vækst og deling. Selvom 
de genetiske ændringers medvirken og funktionen i cancer er rimeligt etablerede, er det epigenetiske 
cancer felt stadig relativt nyt og der er fortsat meget at lære om de epigenetiske ændringers medvirken 
og funktion i cancer. En af de mere grundigt undersøgte epigenetiske ændringer i cancer, er forøget 
DNA methylering ved promoter regioner, som er blevet koblet til undertrykkelsen af for eksempel 
tumor-suppressor gener. Derfor, for at bidrage til forståelsen og udredelsen af hvordan gener kan 
være epigenetisk reguleret i cancer, undersøgte jeg i cancer celle linierne HCT116 og SW480, det 
nyeligt accepterede tumor-suppressor gen, NDRG2, som er blevet påvist at være ned-reguleret i 
mange cancer former og påvirket af forøget DNA methylering. 
Ekspressionen af NDRG2 blev analyseret med Quantitative Real Time Reverse Transcriptase 
Polymerase Chain Reaction (qRT-PCR) og forsøgene viste at NDRG2 niveauet var ned-reguleret i 
begge cancer celle linier. Herudover, blev NDRG2 protein niveauet analyseret med western blotting 
i HCT116 og resultatet viste at NDRG2 også var ned-reguleret på protein niveau i denne celle linie. 
Yderligere, blev NDRG2 promoteren undersøgt med Methylation specific Polymerase Chain 
Reaction (MSP) og ved sekventering, hvilket viste at den tidligere observerede ned-regulering af 
NDRG2 også korrelerede med en forøget DNA methylering af promoter regionen i begge celle linier. 
For at undersøge denne sammenhæng, blev HCT116 cellerne behandlet med det demethylerende stof, 
5-azacytidine, og undersøgt med qRT-PCR. Dette viste, at de behandlede celler havde en signifikant 
forøgelse i udtrykket af NDRG2 i forhold til de ubehandlede celler.  
NDRG2 promoteren blev også undersøgt for MYC og MeCP2 binding med Chromatin 
immunoprecipitation (ChIP) og resultatet blev analyseret med Quantitative Real Time Polymerase 
Chain Reaction (qPCR), for at se om disse proteiner medvirkede til ned-regulering af NDRG2 
udtrykket. Resultaterne viste at MYC kunne binde til NDRG2 promoteren, men at MeCP2 ikke kunne. 
Afslutningsvis, indikerer disse resultater kraftigt, at den for begge celle linier observede ned-
regulering af NDRG2 og ned-regulering af NDRG2 protein, som vist for HCT116 cellerne, er 
forårsaget af methylering af NDRG2 promoteren, og faktisk bliver denne opfattelse understøttet af 5-
azacytidines evne til at genoprette NDRG2 udtrykket in HCT116 cellerne. Yderligere, synes MYC 
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også at være involveret i reguleringen af NDRG2, men udredelsen af denne rolle kræver flere 
undersøgelser. 
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1 INTRODUCTION 
The following paragraphs will provide an introduction to cancer, including an overall description of 
the hallmarks of cancer, proto-oncogenes and tumor-suppressors and some of the genetic changes in 
cancer. This will be followed by a description of the concepts and mechanisms of epigenetic 
modifications, focusing on DNA methylation. Further, will some of the epigenetic alterations in 
cancer be presented and finally the N-myc downstream regulated gene family will be introduced.   
1.1 CANCER 
The word cancer originates from the ancient Greek and is credited to the physician Hippocrates (460-
370 BC), who also is called the “Father of Medicine”. However, even at this time cancer was not a 
new disease. Descriptive evidence of cancer have been found, which dates back to approximately 
3000 years before Christ and was then considered a disease without treatment (American Cancer 
Sociaty 2012). Apparent, our knowledge of cancer biology has grown since this time and has led to 
multiple approaches for prevention, early detection and treatment. Still, even in the twenty-first 
century there is yet a lot to be learned about the biology of cancer. 
Cancer is a leading cause of death and in 2008 it was estimated that cancer accounted for 7,6 million 
deaths worldwide, which corresponded to around 13 % of all deaths this year. As death rates are 
predicted to rise, it is of urgency that we keep on elaborating our knowledge within this field and try 
to elucidate and establish how this disease occur, how we can prevent it and especially how we can 
treat it (WHO 2013).  
Although cancer is really a general term which covers a group of more than 100 diseases, they all 
have the same starting point and occur when a normal cell becomes abnormal and begins to grow out 
of control. In order to build and maintain the normal body, cells most grow, differentiate, divide and 
die in an orderly fashion for the benefit of the organism. Characteristic for cancer cells, is that they 
break these basic rules. In general, cancer cells can be defined by two heritable properties: (1) they 
are able to reproduce them self regardless of normal limitations for growth and cell division, and (2) 
they can invade and colonize other areas of the body (Alberts 2008). Even though cancer can arise in 
one single cell (WHO 2013), it is generally a multistep process where every step provides the cell 
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with a new selectively beneficial advantage and cancer generally arises when enough changes have 
accumulated,  making the cell able to break the basic rules of cells (Alberts 2008; Campbell et al. 
2008). 
1.1.1 THE HALLMARKS OF CANCER 
In 2000, six biological capabilities were proposed to cover the hallmarks of cancer (Hanahan & 
Weinberg 2000). Contained in this premise lays the notion that, in the multistep process in which 
normal cells are transformed into cancer cells, they can acquire a succession of these hallmark 
capabilities, allowing them to become tumorigenic and ultimately malignant. Over the years, these 
six hallmarks have been commonly accepted and demonstrated as being important components of 
many cancers (Hanahan & Weinberg 2011). In 2011, the original six hallmarks were revisited by the 
same authors, resulting in four new additions to the hallmarks of cancer, Figure 1 (Hanahan & 
Weinberg 2011) 
 
Figure 1 – The hallmarks of cancer. The figure depicts 10 characteristics which are considered to be hallmarks in the 
multistep process of tumorigenesis. Figure is edited from Hanahan & Wieiberg 2011. 
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In cancer, any of the hallmarks represented in Figure 1, can principally be described as caused by 
disruption of normal cellular function, leading to an uncontrolled growth and division of the cells. It 
is therefore not surprising that alterations in the genes, involved in sustaining the normal biological 
function of the cell, or their expression, can lead to cancer (Nelson & Cox 2008; Hanahan & Weinberg 
2011). 
1.1.2 PROTO-ONCOGENES AND TUMOR-SUPPRESSORS  
Traditionally the genes involved in cancer, are classified as being either proto-oncogenes or tumor-
suppressor genes (Furney et al. 2012). In normal cells, the products of proto-oncogenes functions as 
proliferative mediators and these genes often encode proteins which function to stimulate cell growth 
and division, and inhibit cell differentiation and cell death (Nelson & Cox 2008; Campbell et al. 
2008). The abnormal or converted version of a proto-oncogene is termed an oncogene and generally 
arises from modifications, which induces gain-of-function of the gene. The proto-oncogene is hereby 
provided with the ability to cause excessive or uncontrolled stimulation of cell growth in an oncogenic 
manner (Lodish et al. 2000).  
The products of tumor-suppressor genes include various proteins with different functions, but 
basically encodes proteins which normally function to inhibit cell division and growth. (Nelson & 
Cox 2008; Campbell et al. 2008). The tumor-suppressor genes generally becomes oncogenic through 
modifications, which results in gene loss-of-function. This loss of function entails that the signals 
which are normally preventive to the cell becomes reduced or lost, leading to uncontrolled cell growth 
and division (Lodish et al. 2000). 
1.1.3 GENETICS AND CANCER 
The gene changes that can lead to cancer are multiple and may be irreversible, as is the case for 
genetic changes as mutations, translocations and copy-number alterations (Furney et al. 2012). For 
example can mutations, when occurring in within the promoter or enhancer, causes gene transcription 
to increase, Figure 2C. Further, can mutations within the coding region cause the gene product to 
become more active or enhance its resistance to degradation, see Figure 2D. If any of these events 
happens to proto-oncogenes, they can be transformed into oncogenes and may lead to the 
development of cancer (Campbell et al. 2008).  
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Translocation of genes can be caused by genomic instability and may lead to the positioning of genes 
under the control of a different and more active promoter, resulting in an increased gene expression. 
Genomic instability may however also cause duplications in gene copy number and thereby cause an 
inappropriate excessive gene expression (Lodish et al. 2000), see Figure 2A and Figure 2B.  
 
 
Figure 2 - Four of the genetic changes that can turn proto-oncogenes into oncogenes. A) The gene is translocated or 
transpositioned, causing it to become under the control of new and more active promoter, leading to excessive 
transcription. B) The gene is amplified, causing the gene to be excessively transcribed. C) A mutation in the promoter 
region causes excessive transcription of the gene. D) A mutation within the coding region of the gene leads to a 
hyperactive or more degradation-resistant gene. Figure is edited from Campbell et al. 2008. 
No matter how the changes come about, any of the above mentioned modifications are genetically 
dominant; that is, it is sufficient that only one of the two alleles contains the oncogene, for the 
induction of cancer (Lodish et al. 2000; Nelson & Cox 2008). 
Tumor-suppressor genes may also be exposed to mutations. However, in order for mutations to 
produce an event that can lead to cancer, the result must be either, a lost or reduced level of 
transcription, which can be caused by a mutation in the promoter region, or a gene product which is 
non-functional or more susceptible to degradation, see Figure 3, usually as a result of a mutation with 
the coding region of the gene. Genomic instability may also, as for oncogenes, result in translocation 
and/or changes in copy number of the tumor-suppressor gene and cause inappropriate gene 
Page 5 of 75 
expression. These events are however only tumor promoting, if the translocation result in a reduced 
transcription of the tumor-suppressor genes, for example if the gene is positioned under the control 
of a less active promoter, or if it entails deletion in copy number, causing the gene to be lost, see 
Figure 3.  
 
Figure 3 - Examples of genetic changes that can cause loss of tumor-suppressor gene expression. Upper picture represents 
the normal and functional tumor-suppressor gene. Middle picture represent a mutation in the coding region of the tumor-
suppressor gene, leading to a NON-functional gene. Bottom picture represents a deletion of the tumor-suppressor gene, 
for example caused by a translocation. Figure is edited from National Cancer Center Research Institute 2010. 
Contrary to the genetic modifications of oncogenes, the changes in tumor-suppressor genes are 
generally genetically recessive and one copy of the gene is normally sufficient to sustain control over 
cell proliferation. Therefore, it requires that the tumor-suppressor gene is inactivated or lost on both 
alleles in order for it to promote cancer (Lodish et al. 2000; Nelson & Cox 2008). 
Classically, cancer have been regarded as a disease caused mainly by mutations and chromosomal 
alterations, which entail changes in the DNA sequence (Baylin & Ohm 2006). However, it is 
becoming increasingly recognized, that the changes in gene expression observed for cancer cells, are 
not exclusively caused by alterations in the DNA sequence, but may also be due to changes in the 
mechanisms regulating the genes, for example epigenetic modifications (Furney et al. 2012). 
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1.2 EPIGENETICS 
The term “Epigenetics” , literally meaning ‘above genetics’, was first introduced by Conrad Hal 
Waddington in the 1940s and was originally meant to describe the study for all molecular processes 
by which a genotype is developed into a specific phenotype (Tost, 2008; Waddington, 2012). Though 
Waddington in some ways were ahead of his time, he did not know about any of the underlying 
mechanisms for his theory, as the structural properties of DNA were not elucidated (Tost, 2008). 
With the discovery of the DNA structure and the subsequent sequencing of a variety of genomes, 
including human, came the acknowledgement that specific phenotypes are not merely a product of 
the genetic sequence (Tost, 2008). A notion which is demonstrated by the central point, that though 
all the cells of a multicellular organism principally contains the same DNA and therefore the same 
genetic information, the cells obviously display distinct morphologic appearances and functions. This 
diversity is a result of differential gene expression, which allows the cells to regulate and express 
different genes in a cell type dependent manner, without subjecting the underlying DNA sequence to 
any modifications (Campbell et al., 2008). 
The expression of genes can be regulated at many levels, but the first level of regulation relies on the 
accessibility of the genes, which is controlled by the way eukaryotic cells arrange their DNA. Because 
eukaryotic cells contain an enormous amount of DNA, when considering the relatively small size of 
the nucleus, the DNA is packed into compacted structures, allowing all of the DNA to fit into the 
nucleus (Alberts, 2008; Campbell et al., 2008).  
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The first level of DNA packaging involves a 
complex formations between the DNA and 
proteins, known as histones, to form units 
termed nucleosomes, see Figure 4. 
These nucleosomes are further tightly packed 
into the structure of chromatin, which is folded 
additionally into the even more compacted 
structure of chromosomes, see Figure 4 
(Campbell et al., 2008). 
The eukaryotic DNA packaging is a central 
point to the understanding of epigenetics, as any 
of the components of chromatin packaging can 
be modified by epigenetic factors. It is important 
to stress, that the epigenetic modifications are 
naturally occurring events, which causes the 
chromosomal structure to either open, 
facilitating transcription, or close, causing 
transcriptional repression (Gilbert & 
Ramsahoye, 2005; Tost, 2008).  
This ability is of crucial importance, for example 
in differential gene expression (descripted 
earlier), but also for the establishment of 
genomic stability, for example in form of 
genomic imprinting and suppression of transposable element movement (Campbell et al. 2008; 
Portela & Esteller 2010).    
Since the introduction, the term epigenetics has been review and re-defined multiple times (Dupont 
et al. 2009) and is currently characterized as the study of reversible heritable and long-term changes 
(which are not necessarily heritable) in gene activity and expression, which are not accompanied by 
changes in the DNA sequence or the sequence of proteins associated with the DNA (Gibney & Nolan, 
2010; LaSalle, Powell, & Yasui, 2013; Tollefsbol, 2009). In this characterization, lays the notion that, 
as epigenetic modification do not involve changes in the underlying DNA, any alterations in the 
 
 
Figure 4 - Organisation of the genome. At the  first level, 
the dobbelstranded DNA is wrapped around histone 
proteins to form units called nucleosomes. The 
nucleosomes are further packaged into the structure of 
chromatin, which is additionally folded into the structure of 
chromosomes, which resides in the nucleus.  
Modified from Tonna et al., 2010 
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epigenetic marks are potentially reversible (Furney et al. 2012) and therefore represent a promising 
therapeutic target. This observation is one of the key motives driving the study of epigenetics 
nowadays, since it is becoming increasingly clear that the abnormalities of cancer cells is not only 
owing to genetic alterations, but also much often includes epigenetic aberrancies (Hatzimichael & 
Crook 2013). 
1.2.1 DNA METHYLATION 
DNA methylation refers to the covalent modification, in which a methyl group (-CH3) is linked to the 
DNA, see Figure 5A. In Humans and other mammals this modification normally occurs at the 5-
position of certain cytosines, which precedes a guanosine, a so-called CpG-dinucleotide (Herman & 
Baylin 2003; Tollefsbol 2011). 
The created 5’-methylcytosine has the same the basepairing abilities as cytosine (Jeltsch 2002), 
Figure 5B. However, because the methyl group is positioned in the major groove, the modification 
alters the presentation of the DNA to DNA binding proteins, which can lead to changes in in 
chromatin structure and gene expression (Jones & Takai 2001).  
The effects of DNA methylation is usually described as associated with transcriptional repression. 
This is however not true for all cases, but relies on the area targeted. DNA methylation may for 
example cause transcriptional repression when targeted a promoter region, but facilitate transcription 
if gene bodies are methylated (Jones & Takai 2001; LaSalle et al. 2013). The function of DNA 
Figure 5 – DNA methylation and basepairing abilities. A) DNA is methylated at the 5’-position of cytosines, creating a 
5’-methylcytosine. B) Basepairing abilities of 5’-methylcytosine with Guanine on the opposite DNA strand.           
Modified from Zakhari 2013 and Gibney & Nolan 2010. 
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methylation at other sites, than at the promoter region, is still not that well understood, but seems to 
play a role in gene splicing and for the activities of enhancer and insulators (Jones 2012). Some of 
the more established roles of DNA methylation in normal cells, includes repression of transposable 
element movement to prevent genomic instability and long-term silencing of for example one of the 
X-chromosomes in females (Jones 2012).  
Repression of transcription by DNA methylation can be causes when promoter region are methylated. 
Because DNA methylation can alter the presentation of the DNA, to for example transcription factors 
(TFs), the DNA methylation can simply prevent the TFs from binding to the promoter region, see 
Figure 6. Another, more indirectly way, is by blocking the accessibility of the DNA via chromatin 
remodeling, which can be accomplished when methylated CpGs are bound by methyl-CpG-binding 
proteins and chromatin remodeling proteins are recruited, causing chromatin condensation and 
thereby gene access prohibition (Brooker et al. 2008), see Figure 6. 
 
Figure 6 – Gene transcriptional repression by DNA methylation at a promoter region. Upper picture represents 
transcriptional repression caused by alterations in DNA presentation to DNA binding proteins. Bottom picture denotes 
transcriptional repression caused by proteins binding to the methylated DNA and recruitment of chromatin remodeling 
proteins. 
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1.2.1.1 CPG-ISLANDS 
As mentioned, DNA methylation targets the dinucleotide CpG. In general the mammalian genome is 
depleted of CpG dinucleotides compared to what would be expected from the overall content of C+G 
bases (Tost 2008). This is explained by a phenomenon called CpG suppression, in which, due to 
spontaneous deamination, the 5’-methylcytosine of CpGs is converted to thymine (Weaver 2005).  
Since this is a natural occurring nucleotide in the DNA, it is not as readily repaired as for example a 
deaminiation of a C to a U (Alberts 2008). If the change is not repaired, the T will basepair with A 
upon the next DNA replication and thereby a point mutation has been created (Weaver 2005). In fact, 
these mutation accounts for about one-third of the single-base mutations that have been observed in 
inherited diseases (Alberts 2008). 
In some regions of the mammalian genome the CpG sites cluster together, creating a so called CpG 
island (Lodish et al. 2000; Brooker et al. 2008). Since their discovery, much attention has been drawn 
to the feature of CpG islands (Bock et al. 2007), as approximately 70% of all genes have promoters 
which are associated with a CpG island and therefore the CpG islands are thought to provide 
prediction of a promoter region (Hackenberg et al. 2010). However, about 80% of all the CpG 
dinucleotides in the mammalian genome are located outside CpG islands. These CpGs are usually 
methylated (Hackenberg et al. 2010; Gibney & Nolan 2010), an observation which does not apply to 
the CpG islands (Antequera 2003), that generally are unmethylated or have relatively low levels of 
methylation (Gibney & Nolan 2010). Because DNA methylation, especially when it occurs in the 
proximity of a promoter region, can regulate gene expression, it is obvious that correct regulation of 
DNA methylation at these sites is of crucial importance for normal gene transcription. 
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1.2.1.2 DNA METHYLTRANSFERASES  
The event of DNA methylation is catalysed by enzymes called DNA methyltransferases (DNMTs), 
which uses S-adenosyl-L-methionine (SAM) as the methyl donor for the transfer of a methyl group 
to the 5-position of cytosine, forming 5-methylcytosine (Jin & Robertson 2013), see Figure 7. 
  
 
In mammals, five members of the DNMT family have been discovered; DNMT1, DNMT2, 
DNMT3A, DNMT3B and DNMTL (Bogdanović & Veenstra 2009). However, only the three of them, 
DNMT-1,-3A, -3B, are enzymatically active on DNA, whereas the members DNMT2 and DNMTL, 
appears to have some non-canonical functions (Bogdanović & Veenstra 2009).  
The DNMT2s were originally considered as part of the DNMT family, due to their highly conserved 
catalytic DNA methyltransferase motif. It has however been shown for various model systems, that 
knock-down of DNMT2, does not to influence DNA methylation. Further, these enzymes have been 
demonstrated to display only weak DNA methyltransferase activity. It has therefore been speculated 
if the DNMT2s methylate substrates other than DNA and have indeed, been shown to methylate small 
RNAs rather than DNA (Jeltsch et al. 2006; Bogdanović & Veenstra 2009). 
Figure 7 - The action of DNA methylatransferases. The DNA methyltransferases uses S-adenosyl-L-methionine (SAM) 
as a methyl donor for the transfer of a methyl group to the 5-position of cytosine, which creates the 5’-methylcytosine. 
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The DNA methyltransferase 3-Like (DNMTL) is, even though it lack the catalytic DNA 
methyltransferase motif and therefore is catalytically inactive, still considered an indispensable 
member of the DNMT family. A variety of functional studies on DNMT3L have shown that 
DNMT3L is required for establishment for genomic imprints and can stimulate the methylation 
activities of DNMT3A and DNMT3B (Suetake et al. 2004; Portela & Esteller 2010; Jurkowska et al. 
2011).  
Based on their structurally and functionally features, the three DNA enzymatically active proteins are 
divided into two distinct groups (Cheng & Blumenthal 2008). One group contains the DNMT3A and 
DNMT3B, also called de novo DNMTs, which are primarily responsible for the initial establishment 
of methylation patterns during the early embryonic development (Law & Jacobsen 2010; Jurkowska 
et al. 2011).  
In mammals the DNA patterns are highly 
dynamic during early embryonic 
development and the genome undergoes 
global demethylating upon fertilisation to 
establish totipotency in the early embryo 
(Jurkowska et al. 2011), see Figure 8.  
Upon the time of implantation, the de novo 
DNMTs establishes the new methylation 
patterns in the somatic cells, see Figure 8. 
Later in life, during the development of 
germ cells, a second round for de novo 
methylation occurs, which is critical for the 
establishment of genomic imprints 
(Jurkowska et al. 2011), see Figure 8.   
The de novo DNA methylation patterns are 
considered to be stable and inheritable 
once established in the somatic cells, a 
feature which is contributed to the 
maintenance of the DNA methylation 
patterns. As the methylation patterns are 
Figure 8 - Dynamic of the mammalian DNA methylation during 
development. Upon fertilization, the zygote undergoes active 
demethylation to generate totipotency in the early embryo. The de 
novo methylation patterns are established in the somatic cells and 
maintain through the organisms lifetime. During germ cell 
development the de novo methylation patterns are set and genomic 
imprinting is established. Modified from Jurkowska et al. 2011. 
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not integrated into the DNA, the patterns are not passed on to the daughter strand during DNA 
replication and cell division. However, a mechanism exist, which ensures that the newly synthesised 
strand is methylated in the same manner as the parental DNA (Jurkowska et al. 2011).   
The DNMT1s are primarily responsible for this maintenance of methylation marks and are therefore 
also called a maintenance DNMTs. The DNMT1 is recruited to hemimethylated DNA upon DNA 
replication, see Figure 9, and maintains the DNA methylation patterns, ensuring that the DNA 
methylation patterns are not lost by passive demethylation, see Figure 9. However, even though the 
DNMT1 has 30 -to -40 fold preference for hemimethylated DNA, it is also involved in de novo 
methylation (Portela & Esteller 2010).  
 
 
 
 
 
 
 
 
 
 
The understanding of the mechanisms establishing and maintaining the DNA methylation marks is 
much more elaborate, than the understanding of the mechanisms erasing the marks. Aside from the 
previously mentioned active demethylation during the development of the early embryo, emerging 
evidence has also reported on active demethylation in somatic cells (Franchini et al. 2012). Although 
Figure 9 - Overview of the DNA methylation dynamics in mammals. The methylation patterns are set de novo on 
unmethylated DNA. Upon replication, the patterns are reestablished on the new hemimethylated strand through 
maintenance DNA methylation and passive demethylation occurs if the methylation patterns are not maintained. Active 
demethylation occurs during early embryonic development and functions to generate totipotency in the developming 
embryo. The unmethylated and methylated DNA is able to influence the chromatin structure and gene regulation. The 
hemimethylated DNA requites DNMT1.  
Modified from Jurkowska et al. 2011.    
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it is still not well understood have this is accomplished, some mechanisms have been proposed. One 
idea is that the methylation marks are disrupted by shifts in pH within the cell. As local changes in 
pH is a common cellular mechanism, used for example to influence biological activity of enzymes, 
this mechanism is indeed possible. However, it have also been proposed, that there exist special 
enzymes which performs the demethylation. This seems possible, as it has been shown for some other 
epigenetics modifications, that there exist enzymes for both the establishment and for the reversal of 
a given modification. In fact, has some of the enzymes which are known to be involved in DNA 
methylation also been linked to the process of demethylation, but these mechanisms are however not 
fully elucidated (Franchini et al. 2012). 
1.2.1.3 METHYL-CPG-BINDING PROTEINS 
DNA methylation of CpG islands is in general associated with a dense chromatin structure and 
silencing of genes (Parry & Clarke 2011) and as mentioned earlier, transcriptional activation can be 
directly inhibited by the existence of DNA methylation, due to its prevention of transcription factor 
binding. Transcriptional activation may however also be caused by a mechanism, which involves the 
recruitment of proteins that can bind to the methylated CpGs (Bogdanović & Veenstra 2009). These 
proteins are known as methyl-CpG binding proteins and are considered to interpret the signal that the 
methylated DNA presents (Lan et al. 2010). Apart from their ability to bind methylated CpGs, they 
are capable of association with, and recruitment of various histone modifiers and chromatin 
remodeling complexes (Jaenisch & Bird 2003; Bogdanović & Veenstra 2009; Portela & Esteller 
2010). By this, they provide a key link between the patterns of DNA methylation, histone 
modifications and chromatin remodeling.   
The methyl-CpG binding proteins constitutes a group of proteins which is be subdivided into 3 
branches on account of their structure: 1) the methyl-CpG binding domain (MBD) containing 
proteins, 2) the methyl-CpG binding zinc fingers or kaiso and kaiso-like proteins, 3) the SET and 
RING finger-associated (SRA) domain containing proteins (Parry & Clarke 2011).  
The original identification of the methyl-binding proteins, was based on the ability to bind methylated 
CpGs through the MBD and the first true member was MeCP2, which selectively recognizes 
methylated CpG (Ballestar & Wolffe 2001). Today the MBD containing proteins compromises the 
largest group of the methyl-binding proteins, which also includes proteins that do not directly bind 
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methylated DNA (Parry & Clarke 2011) and some of the more accepted members are; MePC2, 
MBD1, MBD2, MBD3 and MBD4 (Bogdanović & Veenstra 2009; Zou et al. 2012). All of the 
members share the MBD and prefers to bind methylated DNA, but otherwise have very distinct 
domains and interacting capabilities. An exception is MBD3, which do not bind methylated DNA 
owing to a disruption of the MBD (Bogdanović & Veenstra 2009; Zou et al. 2012), but instead is an 
important part of the repressive ATP-dependent chromatin remodeling complex, Mi-2/NuRD 
(Bogdanović & Veenstra 2009; Parry & Clarke 2011). 
The additional domains of the MBD proteins are as mentioned diverse, which points to them having 
various biological functions. For example, the MeCP2, MBD1 and MBD2 all contains a 
transcriptional repression domain, which accounts for their repression ability. Further the proteins 
also have different interacting abilities on account of their other different domains. The MBD1 is for 
example able to associate with specific chromatin remodeling complexes and histone 
methyltransferases, to mediate transcriptional repression, whereas MBD2 mostly associates with 
histone deacetylases and chromatin remodeling complexes as the Mi-2/NuRD, where it mediates the 
function of methyl binding (Bogdanović & Veenstra 2009; Parry & Clarke 2011). The functions of 
MBD4 is somewhat more distinct, as it is known to be involved in DNA mismatch repair and targets 
sites where methylated cytosines have been deaminated, to maintain the methylated CpG. In addition 
MBD4 has been shown to possess some repression abilities, which are thought to be mediated through 
interactions with specific histone acetylases and co-repressor complexes (Tost 2008; Bogdanović & 
Veenstra 2009). 
MeCP2 is probably the most thorough studied member of the MBDs and several functions have been 
described for this protein (Bogdanović & Veenstra 2009; Gibney & Nolan 2010). As some of the 
other members of the MBD family, MeCP2 contains transcriptional repression domain and have been 
reported to associate with various co-repressor complexes and histone deacetylases, to cause 
transcriptional repression (Bogdanović & Veenstra 2009; Parry & Clarke 2011). Further the MeCP2 
have also been reported to interact with histone methyltransferases and members of the ATP-
dependent chromatin remodeling complex family (Tost 2008). Also some more alterative functions 
of MeCP2 have been suggested and include an ability to bind methylated CpGs without causing 
transcriptional repression. This notion, is based on observations showing that MeCP2 also is capable 
of binding hemimethylated DNA and that it can interact with DNMT1, indicating that it could be 
involved in maintenance of DNA methylation (Tost 2008).     
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The methyl-CpG binding zinc finger proteins are named after their 3-zinc finger motif which is 
capable of binding a pair of methylated CpG dinucleotides. These proteins have multiple functions 
depending on their cellular location and have been reported capable of binding both methylated and 
unmethylated promoters, leading to transcriptional repression (Parry & Clarke 2011). 
The members of the SRA domain containing proteins, all have a preference for hemimethylated DNA 
and their function is mostly concerned with their ability to recruit DNMT1 and ensure correct 
establishment of methylation patterns upon replication (Parry & Clarke 2011).      
 
1.2.2 OTHER EPIGENETIC MODIFICATIONS 
1.2.2.1 HISTONE MODIFICATIONS 
Histone proteins are components of eukaryotic chromatin and provide the first level of chromatin 
packing (Campbell et al. 2008). As descripted in section 1.2, the histone proteins serve to order and 
pack DNA into the structural units known as nucleosomes. The organization is accomplished due to 
the histone proteins being positively charged, because of their rich amount of arginine and lysine, 
which accounts for approximately one-fourth of the total amino acid residues (Campbell et al. 2008; 
Nelson & Cox 2008) and the biochemical properties of DNA, which owing to the phosphate groups 
along the backbone, causes the DNA strand to be negatively charged on the outside (Campbell et al. 
2008). Features, which taken together make the histones capable of binding DNA very tightly 
(Campbell et al. 2008; Nelson & Cox 2008). 
Based on their amino acid composition and molecular weight, the eukaryotic histones are divided 
into five major classes; H1, H2A, H2B, H3 and H4 (Nelson & Cox 2008) The histones H2A, H2B, 
H3 and H4 are called the core histones and are highly conserved across eukaryotes (Mariño-Ramírez 
et al. 2011). For instance, the H4 histone molecules of peas and cows only differ in 2 out of 102 amino 
acid residues. Similarly, only 8 residues differ between the human H4 and that of yeast (Nelson & 
Cox 2008). H1 is called a linker histone and is not considered to be as well conserved (Alberts 2008). 
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In the nucleosome DNA-protein complexes, the DNA is wrapped around an octameric assembly of 
core histones, which is made up from a central tetramer of H3-H4 and two adjacent H2A-H2B dimers 
(Mariño-Ramírez et al. 2011), see Figure 10.    
 
 
Figure 10 - Overview of the assembly of the histone octamer and the structure of nucleosomes. The core histones are first 
assembled into H2A-H2B dimers and a H3-H4 tetramer, which comes together to produce the histone octamer. For each 
histone octamer, the DNA is bound to and wrapped about 1.7 turns around, to form units called nucleosomes. 
The nucleosomes are separated from each other by a region called linker DNA, which can range from 
a few base pairs up till about 80 base pairs (Alberts 2008). On average the nucleosomes are spaced 
about 200 base pairs from one another, with ~146 base pairs wrapped around the octamer (Nelson & 
Cox 2008). This organization of chromatin is often referred to as “beads on a string”, because of its 
appearance under an electron microscope (Alberts 2008). The H1 histone binds the linker DNA and 
is involved in the further packing of the chromatin fiber (Campbell et al. 2008; Nelson & Cox 2008). 
Each of the core histones shares the common features, “histone fold” domains and an N-terminal 
extension. In the nucleosomes, the histone fold domains occupy the majority of the internal structure. 
Here, it contributes to the histone:DNA interactions needed for the wrapping of DNA around the 
octamer (Luger & Collins 2001; Suganuma & Workman 2011). The N-terminal extension is known 
as the histone tail and appears unstructured in crystal images (Campbell et al. 2008; Suganuma & 
Workman 2011). These tails protrude from the nucleosome, into the surroundings and are able to 
form interaction with adjacent nucleosomes. Additionally important, they are the target of 
modifications which do not only have direct impact on chromatin structure, but have the ability to 
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recruit remodeling complexes which uses ATP to alter chromatin structure (Bannister & Kouzarides 
2011). 
Histone modifications refer to the addition or removal of a specific chemical group, of which many 
are executed on the histone tails (Campbell et al. 2008), but in some cases also on the nucleosome 
core (Alberts 2008). To date, many modifications have been discovered (Bannister & Kouzarides 
2011; Molina-serrano & Kirmizis 2013), however some of the more well characterized include; 
acetylation, methylation, phosphorylation and ubiquitylation (Molina-serrano & Kirmizis 2013), see 
Figure 11. 
 
 
Figure 11 - Overview of possible histone modifications. The N-terminal constitutes the tail of histones and the C-terminal 
holds the histone fold domain. The represented modifications include; acetylation (purple Ac), methylation (green Me), 
phosphorylation (blue P) and ubiquitylation (pink Ub). Figure is modified from Rodriquez-Paredes & Esteller 2011. 
Histone acetylation is the addition of an acetyl group onto the ɛ-amino group of lysine (K) side chains, 
see Figure 11. The transfer is catalyzed by histone acetyltransferases (HATs), which uses acetyl-CoA 
as a donor of the acetyl group. The opposing reaction is performed by histone deacetylases (HDACs) 
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(Alberts 2008; Bannister & Kouzarides 2011). Acetylation of lysines causes neutralization of the 
original positive charge, thereby reducing the histones affinity for the DNA (Alberts 2008; Bannister 
& Kouzarides 2011) and accordingly, this modification is almost always associated with 
transcriptional activity (Kouzarides 2007). 
Methylation of histones is achieved by histone methyltransferases (HMTs). The HMTs transfers a 
methyl group from the donor, SAM (Black et al. 2012), and onto either lysine or arginine (R) residues 
(Bannister & Kouzarides 2011), see Figure 11. Further complexity is added in that, the lysines can be 
mono-, di- or tri-methylated and guanine may be symmetrically mono- or di- methylated or 
asymmetrically dimethylated (Bannister & Kouzarides 2011). Additionally, methylation has been 
implicated in both transcriptional activation and repression, depending on the residue modified 
(Kouzarides 2007; Varier & Timmers 2011). 
Histone phosphorylation refers to addition of a phosphate group. This modification can occur on 
serines (S), threonines (T) and tyrosines (Y), see Figure 11, and is mainly found on the histone tail 
(Bannister & Kouzarides 2011). The phosphate is transferred from ATP and is brought about by a 
variety of kinases (Bannister & Kouzarides 2011; Banerjee & Chakravarti 2011). The 
phosphorylation adds a negative charge to the histone, which brings about alterations in chromatin 
structure to facilitate transcriptional activity. Indeed histone phosphorylation has been linked to 
numerous cellular processes including transcription, DNA repair, apoptosis, mitosis and chromatin 
condensation (Banerjee & Chakravarti 2011; Rossetto et al. 2012). 
The addition of ubiquitin takes place at lysine residues, see Figure 11. Though this modification is 
relatively large, it is still highly dynamic. The ubiquitynation is performed by a complex of three 
enzymes, which interplay to transfer the protein onto the histone. As for many of the above mentioned 
modifications, ubiquitynation can cause multiple outcomes and has been associated with 
transcriptional activation and repression, DNA damage response and transcriptional elongation  
(Kouzarides 2007; Bannister & Kouzarides 2011; Cao & Yan 2012). 
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1.2.2.2 CHROMATIN REMODELING COMPLEXES 
The packaging of DNA and histones into the units of nucleosomes constitutes a barrier to the DNA-
proteins interactions necessary for transcription and therefore the positioning and composition of the 
nucleosomes is able to regulate gene expression (Portela & Esteller 2010). For example can the 
positioning of nucleosomes around a transcription start site inhibit the binding of transcription factors 
or the assembly of the transcription machinery. Further, the histone composition of the nucleosome 
can influence how tightly the DNA is bound and thereby the accessibility of the DNA (Alberts 2008).  
To overcome the nucleosome barrier, the eukaryotic cell contains multiple enzymes, which can 
arrange the position and composition of the nucleosomes, using the energy of ATP hydrolysis. These 
enzymes arrange themselves into large complexes, known as ATP-dependent chromatin remodeling 
complexes (Gibney & Nolan 2010; Portela & Esteller 2010). The ATP-dependent chromatin 
remodeling complexes can alter the chromatin structure in various ways, to either facilitate or repress 
gene transcription.  
As can be visualized from Figure 12A, the remodelers can alter the histone-DNA binding, which may 
lead to the unwrapping of the DNA, thereby facilitating the access of DNA binding proteins, which 
may act in an transcriptional activating or repressive manner. Further, the sliding of nucleosome may 
lead to the exposure of a gene, but can also lead to condensation of the chromatin structure, thereby 
occluding factors from binding, see Figure 12B. The remodeler complexes may additionally modify 
the chromatin to eject nucleosomes (Figure 12C), exchange histones (Figure 12D) or eject histone 
dimers (Figure 12), which are all modifications that can lead to the exposure of  genes and may 
facilitate or repress transcription (Clapier & Cairns 2009).  
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Figure 12 - Chromatin remodeling mechanisms of ATP-dependent remodeling complexes. The ATP-dependent 
remodeling complexes uses the energy of ATP hydrolysis to rearrange the position and composition of the nucleosomes, 
to make genes (indicated as red) more or less accessible. A) The DNA is unwrapped from the histones, making the gene 
more available. B) Nucleosome sliding may either cause genes to become more or less accessible. C) Nucleosome ejection 
changes the chromatin compaction and causes genes availability. D) + E) Exchanging histone variants and histone dimer 
ejection both changes the nucleosomes composition, which may influence DNA binding and thereby the DNA 
accessibility. Based upon Clapier & Cairns 2009. 
The ATP-dependent chromatin remodeling complexes all share the ATPase domain, but otherwise 
differ in their unique subunit composition, which allows for their separation into the four families; 
SWI/SNF, ISWI, CHD and INO80 (Portela & Esteller 2010). All of the different family complexes 
are able to regulate the chromatin structure in various ways, but some may mostly be involved in 
particular events (Clapier & Cairns 2009). 
The SWI/SNF family has many activities, but is mainly known to slide and eject nucleosomes to 
expose the DNA and allow for DNA binding proteins to access the DNA, see Figure 12B and Figure 
12C. This action may facilitate transcription, if transcription factors are allowed to bind, but may also 
allow the binding of factors which are involved in transcriptional repression (Clapier & Cairns 2009; 
Portela & Esteller 2010). 
Many of the members of the ISWI remodeler family functions to organize nucleosomes by the action 
of nucleosome sliding, leading to chromatin assembly and transcriptional repression (Figure 12). 
However, a certain complex of this family, NURF, is known to facilitate transcription. This complex 
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is capable of randomizing the nucleosome spacing, leading to a more open chromatin structure and 
access of RNA polymerase II to the DNA (Clapier & Cairns 2009; Portela & Esteller 2010).  
The function of CHD remodelers is very diverse and depending on proteins associated with the 
complex, they can either slide or eject nucleosomes to promote transcription, but may also have 
repressive roles. One of the repressive members of the CHD family is the Mi-2/NuRD complex, 
which additionally to its ATPase also contains histone deacetylases (HDACs) and methyl CpG-
binding domain (MBD) proteins (Clapier & Cairns 2009; Portela & Esteller 2010). 
The members of the last group, the INO80 remodelers, have very diverse functions and are all 
involved in chromatin remodeling by their ability to remove and displaces certain histone variants 
(Clapier & Cairns 2009), but have also been shown to participate in processes as transcriptional 
activation, DNA repair and DNA replication (Portela & Esteller 2010). 
1.2.2.3 NON-CODING RNAS 
Analyses have shown that eukaryotes transcribe up to 90% of their genome, however only 1-2% of 
these transcripts encode proteins and the rest is refer to as non-coding RNAs (ncRNAs) (Kaikkonen 
et al. 2011). Previously, it was though that these ncRNAs were just “junk DNA” and they did not 
exert any biological function. It is however becoming increasingly recognized, that these ncRNA in 
fact play crucial roles in higher organisms (Zhou et al. 2010).  
The ncRNAs can be classified based on their length and function, and some of the more well-
established roles of ncRNAs, are that of microRNAs (miRNAs) and small interfering RNAs 
(siRNAs). In general, these two ncRNA have very similar roles, and both function to bind mRNAs, 
causing their repression or degradation (Tost 2008; Zhou et al. 2010).  
Besides their individual biological function, many ncRNAs have been shown to interact with the other 
epigenetic modifiers, for example DNA methylation. A classic example is the involvement of 
ncRNAS in X-chromosome inactivation, where the ncRNA XIST in association with some other 
chromatin proteins and DNA methylation, is able to inactivate one of the female X-chromosomes. 
Further evidence for the relationship between ncRNA and DNA methylation lays in the observation, 
that for many imprinted genes (which generally involves DNA methylation), ncRNAs exists which 
can bind to the same or a nearby region and are involved in the silencing process (Costa 2008).   
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1.3 EPIGENETICS AND CANCER 
Traditionally the development of cancer has been considered as a process caused by genetic defects, 
which altered gene expression due to the events as mutations, deletions, amplifications and 
translocations. It is however becoming commonly recognized, that these genetic events are not the 
only processes which can alter gene expression and lead to tumorigenesis  (Sandoval & Esteller 2012; 
Hatzimichael & Crook 2013) and in fact the existence of epigenetic changes seem to be a common 
hallmark of cancer (Sharma et al. 2010). This observation is however not surprising, when 
considering that the epigenetic machinery is an essential player in gene regulation and maintenance 
of genomic stability, both of which are commonly disrupted in cancer. 
The epigenetic machinery may in principle be disrupted at any level and can lead to unfavorable gene 
silencing or transcription, which in itself can favor tumorigenesis. The first link between the 
epigenetic machinery and cancer, was associated with aberrant DNA methylation (Sandoval & 
Esteller 2012). In general the consequence of aberrant DNA methylation is thought to be either 
repression of transcription due to excessive DNA methylation (hypermethylation), or enhancement 
of transcription due to loss of DNA methylation (hypomethylation). The transcriptional repression 
can for example be caused by hypermethylation at promoter regions and is in cancer cells often 
associated with silencing of tumor-suppressor genes (Tollefsbol 2009; Furney et al. 2012), see Figure 
13A. The promoter region may however also be hypomethylated, causing an increased gene 
expression, which may contribute to the activation of oncogenes, see Figure 13B. Furthermore, 
hypomethylation is also associated with loss of imprinted genes and genomic instability 
(Hatzimichael & Crook 2013). 
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Figure 13 - Effects of excessive or decrease methylation at promoter regions. A) Excessive methylation prevents 
transcription factor from binding and the tumor-suppressor cannot be expressed. B) Decreased methylation allows binding 
of transcription factors and the oncogene is activated. Figure from Nelson 2008. 
Aberrant DNA methylation is not the only epigenetic mechanism which can be deregulated, also 
alterations in histone modifications and abnormal chromatin remodeling is observed in cancer cells. 
Some of the deregulated histone modifications which have been reported for cancer cells, includes 
that of histone acetylation and methylation (Sharma et al. 2010). Normally, histone acetylation is 
associated with an open chromatin structure, which allows gene expression, whereas histone 
methylation may cause both transcriptional repression and activation. In several cancer cells, the 
histones have been found deacetylated, an observation which correlates with an upregulated level and 
activity of HDACs, the proteins responsible for the deacetylation and deletion or mutations in the 
HATs, the proteins which are associated with the establishment of the acetylation marks. The levels 
of histones methylation have also been shown to be decreased or increased for cancer cells, which 
respectively, can lead to an increased or decreased transcriptional expression, and also these marks 
are associated with and aberrant expression of the proteins responsible for the establishment and 
maintenance of the histone methylation marks (Sharma et al. 2010; Portela & Esteller 2010).  
Disruption of the normal nucleosome position in cancer has been linked to the action of ATP-
dependent chromatin remodeling complexes, however it is still unclear how this is accomplished. 
Some of the normal functions of the complexes are to locate the nucleosomes at the right position 
relative to transcription start sites and to organize composition of histones, mechanisms which both 
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are able to influence the accessibility of the DNA to DNA binding proteins, including transcription 
factors (Clapier & Cairns 2009; Portela & Esteller 2010). It therefore does not seem surprising, that 
any disruption of the ATP-dependent chromatin remodeling complexes, can cause an abnormal 
regulation of the chromatin structure, resulting in an unfavorable enhanced or repressed 
transcriptional state. 
As previously mentioned, tumorigenesis is a multistep process and may therefore involve both genetic 
and epigenetic alterations (Hatzimichael & Crook 2013). An example of this cooperation has for 
example been studied extensively in the human colon cancer cell line HCT116. These cells contains 
multiple mutations, which have inactivated tumor-suppressor genes or activated oncogenes, leading 
to disruption of cellular pathways and function. In addition to these mutations, the cells contain 
several growth-control genes which have been shown to be silenced by epigenetic alterations. 
Experiments have shown that treated the cells with epigenetic therapeutic agents can reactivation 
these epigenetically silenced gene and lead to reduced proliferation and apoptosis. Further, analysis 
of specific genes have shown that while one allele is mutated in these cells, the other becomes 
epigenetically silenced. In this way, the genetic and epigenetic changes can collaborate to inhibit 
transcription in cancer cells (Hatzimichael & Crook 2013).  
 
 
 
 
 
 
 
 
 
 
 
Page 28 of 75 
 
  
Page 29 of 75 
1.4 THE N-MYC DOWNSTREAM REGULATED GENE 
The human N-myc Downstream Regulated Gene (NDRG) family is constituted of four members; 
NDRG1, NDRG2, NDRG3, NDRG4. On amino acid level the members are between 57 % and 65 % 
identical and show more than 90 % similarity to their mouse orthologs. Furthermore, the members 
are highly evolutionary conserved, showing orthologs not only in mammals, but also in invertebrates 
and plant, providing additional proof that this gene family exerts important biological function (Zhou 
et al. 2001). 
All members of the NDRG family possess an α/β-hydrolase fold domain (Shaw et al. 2002). The α/β-
hydrolase fold family encompasses a wide variety of different proteins, which have been grouped 
together based on structural features of the fold (Lenfant et al. 2013). The features that seem to be 
essential to the α/β-hydrolase fold includes; at least five parallel β-strands, a catalytic triad in the 
order nucleophile-acid-histidine, and the presence of a nucleophile elbow (Nardini & Dijkstra 1999; 
Shaw et al. 2002). The α/β-hydrolase fold forms a stable scaffold for multiple enzymes (Hwang et al. 
2011) and include members that are catalytical active (e.g. lipases, esterases and peptidases) and some 
which are inactive (e.g. glutactin, neuroligins and yolk proteins)(Lenfant et al. 2013). 
In the NDRG family, the 
nucleophile- and histidine residues 
of α/β-hydrolase fold are replaced by 
glycines and they therefore lack two 
of the three residues within the 
catalytic triad, see  Figure 14, and 
consequently, the proteins do not 
possess catalytic activity (Shaw et al. 
2002; Hwang et al. 2011).  
However, since the features which provides the overall fold structure has been conserved, the α/β-
hydrolase fold domain seems likely to be involved in some part of biological function that the NDRG 
family exerts (Hwang et al. 2011).  
 
 Figure 14 - Comparison of the three catalytically triads of the typical α/β-
hydrolase to that of the NDRG family. Figure from Shaw et al. 2002. 
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The precise function and regulation of the NDRG family is still not fully understood, but through 
multiple studies in various model systems and under diverse condition, all of the family members 
have been linked to cell proliferation, differentiation, development and stress responses. Furthermore, 
the members have all been shown deregulated in cancer, indicating that these proteins may play an 
important role in tumorigenesis (Melotte et al. 2010).  
1.4.1  NDRG1 
NDRG1 was the first member of the NDRG family to be discovered. It was originally found in a 
search for genes which were responsive to elevated levels of homocysteine, a risk factor for vascular 
diseases. NDRG1 was found to be up-regulated and was called RTP (reducing agent and tunicamycin-
responsive protein) (Kokame et al. 1996). The following years, researchers cloned this gene from 
multiple cell types, under various circumstances and the gene was given multiple names (Li & 
Kretzner 2003). It was however not until 1999, when Shimono and coworkers discovered that this 
gene was associated with N-myc, that it was given the name; N-myc Downstream Regulated Gene 
(Shimono et al. 1999; Li & Kretzner 2003). The name was based on the findings that this gene was 
upregulated 20-fold in N-myc deficient mice, showed an inverse relationship in expression patterns 
to N-myc in wildtype and had repressed promoter activity by N-myc and N-myc:Max (Shimono et 
al. 1999). 
NDRG1 mRNA is ubiquitously expressed in human tissues (Lachat et al. 2002; Ellen et al. 2008), 
where it is primarily localized in the cytoplasm, but can also be found in the nucleus (Stein et al. 
2004). NDRG1 have been thoroughly studied and is shown to be involved in cellular events as; stress 
response, proliferation and differentiation (Melotte et al. 2010).                                                                 
Cellular stress caused by hypoxia, have shown to induce NDRG1 expression, and probably reflecting 
the often hypoxic state of the cancer cells, NDRG1 have been observed overexpressed in several 
cancers compared to normal tissue (Cangul 2004). In cells subjected to DNA damage, NDRG1 has 
been shown to be induced by the pro-apoptotic protein p53 and to be necessary for p53-mediated 
apoptosis (Stein et al. 2004). However, NDRG1 have also showed a reducing effect on p53 expression 
under both standard and hypoxic conditions (Chen et al. 2006). These observations taken together, 
indicate that NDRG1 exert negative feedback on p53 and may function as a mediator, linking hypoxia 
and p53-mediated response (Chen et al. 2006; Ellen et al. 2008). Further, NDRG1 have demonstrated 
an inhibitory effect on cell proliferation, which was specific for metastatic lung cancer cells, 
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indicative of NDRG1 as a suppressor of cell growth in metastatic tumor cells (Stein et al. 2004). 
NDRG1 expression has also shown to correlate with differentiational state and cell growth. Various 
cell differentiation signals, including retinoids and vitamin D, which are able to inhibit growth and 
cause diffententiation, have shown to induce NDRG1 expression (Ellen et al. 2008). This correlation 
has been additionally studied by overexpression of NDRG1, which have shown that NDRG1 is able 
to enhance differentiation and inversely, that silencing can have a diminishing effect on 
differentiation and also on viability (Chen et al. 2006).  
Besides the indications that NDRG1 is involved in cellular stress response and is able to inhibit 
proliferation and differentiation, NDRG1 is the only one of the NDRG family members which have 
been directly linked to a biological function. Mutations in NDRG1, causing an altered NDRG1 
protein, have been identified and directly linked to the demyelinating disorder, Charcot-Marie-Tooth 
Disease (Hunter et al. 2003; Ricard et al. 2013). 
1.4.2 NDRG3 
Contrary to ndrg1, ndrg3 is not upregulated in N-myc mutant mice, indicating that this paralog is 
differently regulated (Okuda & Kondoh 1999). NDRG3 have been shown to be expressed in various 
human tissues, showing high expression in brain, heart and kidneys (Zhou et al. 2001; Zhao et al. 
2001), but with the highest expression in ovary, testis and prostate. Further, a study with in situ 
hybridization of mouse testes has shown that a ndrg3 positive signal was especially expressed in cells 
involved in spermatogenesis (Zhao et al. 2001). In 2009, Wang et al. verified that testis and prostate 
are highly enriched in NDRG3 expression, but also showed that NDRG3 was detectable for 58.6 % 
of prostate cancer tissues compared to only 13.2 % of benign prostatic hyperplasia. Indicating that 
there could be a correlation between the expression profile and prostate cancer (Wang et al. 2009). 
They further showed that overexpression of NDRG3 in prostate cancer cell line PC-3, could increase 
cell growth rate and migration, up-regulate angiogenic chemokines and promoted growth of 
xenografted tumors in nude mice. All results which indicate that NDRG3 is a tumor promoter and 
that its overexpression could contribute to a malignant phenotype of tumors (Wang et al. 2009). 
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1.4.3 NDRG4 
Compared to the relatively ubiquitous expression of the other family members, NDRG4 have shown 
to be rather specifically expressed in brain and heart. An expression pattern which further was shown 
to increase from fetal stage until adult (Zhou et al. 2001). Since NDRG4 is selectively expressed in 
the brain, several studies have been dedicated to elucidate its role in this area, but with some 
contradictory results (Melotte et al. 2010). NDRG4 have been shown to be markedly down-regulated 
in Alzheimer’s disease (Zhou et al. 2001) and reduced levels of NDRG4 have shown to inhibit neurite 
outgrowth in PC12 cells (Ohki et al. 2002). Further, NDRG4 have been found to be significantly 
down-regulated in glioma brain tumors compared to non-neoplastic brain tissue and that a decreasing 
expression of NDRG4 correlated with increasing pathological glioma grade, indicating that 
downregulation of NDRG4 could influence glioma development. In addition, it was showed that there 
was an inverse correlation between NDRG4 expression and survival, as patients with abundant 
expression had better overall survival (Shanqu Li et al. 2013).  
In the aggressive brain tumor form, glioblastoma multiforme (GBM), it was found that NDRG4 was 
down-regulated at both mRNA and protein level and that overexpression was able to reduce cell 
proliferation in this cell type (Ding et al. 2012). However, a study by Schilling et al. has also shown 
that NDRG4 expression was in fact increased in GBM and that NDRG4 expression was required for 
cell viability, as loss of expression lead to cell cycle arrest and apoptosis in vitro. They further showed 
that knock-down of NDRG4 could decrease growth of GBM xenografts in mice  (Schilling et al. 
2009). Although these results seem conflicting, they could merely reflect some heterogeneity of 
NDRG4 expression in GBM, as also emphasized by Ding et al. (Ding et al. 2012).  In line with the 
observations for gliomas, NDRG4 has also been shown to be reduced in colorectal cancer tissue 
compared to non-cancerous colon mucosa and that overexpression led to suppressed colony 
formation, cell proliferation and migration.  
1.4.4 NDRG2 
In normal tissue, NDRG2 is highly expressed in the brain, heart, salivary glands and skeletal muscles. 
A more moderately expression is seen in the liver, kidneys, adrenal glands and trachea, whereas the 
lowest expression is observed in tissues as colon, lung and bone marrow (Qu et al. 2002; Deng et al. 
2003). As NDRG2 is normally highly expressed in the brain, early studies on this gene have tried to 
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elucidate the role of NDRG2 within this area. It has for example been shown that levels of NDRG2 
is elevated during the time of neurite growth, that NDRG2 locates to the cell membrane during growth 
and that NDRG2 overexpression was able to promote neurite elongation (Takahashi et al. 2005). 
Further, NDRG2 was shown to be up-regulated in the brain of Alzheimer’s patients, when compared 
to normal brain tissue and expression was shown to locate to areas which are known to be associated 
with the pathology of the disease (Mitchelmore et al. 2004). Although these results all points to 
NDRG2 having a biological role in normal brain development and physiology, the precise function 
of NDRG2 has not been clarified.   
Newer studies on NDRG2 have focused on its role in cancer and based on the numerous studies on 
NDRG2’s role in cancer, it is now considered a tumor suppressor gene. This role is demonstrated by 
various studies on both cancer cell lines and cancer tissues showing that NDRG2 down-regulation, at 
both mRNA and protein level, is associated with increased cell growth, tumor malignancy and 
decreased patient survival (Lee et al. 2008; Melotte et al. 2010; Lorentzen & Mitchelmore 2012). 
In regards to the regulation of NDRG2, it is still not well understood how this is accomplished. In 
vivo studies in N-myc deficient mice have shown that contrary to ndrg1, ndrg2 regulation is not 
affected by this genotype (Okuda & Kondoh 1999). However, it has also been shown that in several 
experimental cell lines, the NDRG2 mRNA and protein levels correlates inversely with Myc levels 
and that that Myc can interact with the core promoter of NDRG2 (Zhang et al. 2006). Although the 
inverse correlation between NDRG2 and MYC has been further investigated and reported for thyroid 
and colorectal cancer (Zhao et al. 2008; Shi et al. 2009), Lorentzen et al. 2011 were not able to show 
this correlation in thyroid and breast cancer, and therefore suggested that MYC might not be a 
regulatory suppressor of NDRG2 (Lorentzen et al. 2011). Another regulatory mechanism which have 
been investigated for NDRG2, is repression by ncRNA. A study by Feng et al. 2011 has reported that 
NDRG2 contains a sequence which can be recognized by the ncRNA, miR-650, and that NDRG2 was 
down-regulated at protein level in cell transfected with the miR-650 (Feng et al. 2011). Further, these 
authors showed that regulation of NDRG2 may also be caused by epigenetic modifications, like DNA 
methylation. In line with this, several studies have now reported that the down-regulation of NDRG2 
observed for many cancers is correlated with aberrant DNA methylation and that treatment with 
various demethylating agents can re-establish expression (Piepoli et al. 2009; Feng et al. 2011; 
Lorentzen & Mitchelmore 2012).   
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2 AIM  
Cancer is a leading cause of death in modern society and is considered to be caused by both genetic 
and epigenetic alterations. The transformation of normal cells into cancer cells capable of 
uncontrolled growth and division, often includes the activation of oncogenes and/or inactivation of 
tumor suppressor genes and thus, much current cancer research is engaged in elucidating these 
mechanisms.  
The recently classified tumor suppressor gene, NDRG2, is often down-regulated or absent in cancer, 
which is an expression profile that have been shown to correlate with increased DNA methylation at 
the promoter region. Therefore the aim of this Master thesis was to identify and elucidate how 
NDRG2 expression can be epigenetically silenced in cancer.  
Using the human colorectal cancer cell line, HCT116, and human colon adenocarcinoma cancer cell 
line, SW480, as a model system, some of the more specific goals were: 
- To analyse NDRG2 expression, at both mRNA and protein level 
- To evaluate the methylation status of the NDRG2 promoter 
- Try to restore NDRG2 expression by treatment using the demethylating agent, 5-azacytidine 
- Investigate if the DNA methyl-binding protein, MeCP2, binds to the methylated NDRG2 
promoter 
- Investigate if the transcription factor, MYC, binds to the methylated NDRG2 promoter 
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3 METHODS AND MATERIALS 
This paragraph will provide an overview of the methods and materials used for the various 
experiments performed. Formulas for some materials are found at the back of the paragraph, which 
will be denoted with an asterisk (*) in the text. 
3.1 CANCER CELL LINES, GROWTH CONDITIONS AND HARVESTING 
Cancer cell lines used, were human colorectal cancer cell line HCT116 and human colon 
adenocarcinoma cell line SW480, which were already in use in the laboratory. 
Cell lines were grown in T25 or T75 culture flasks supplied with growth media (McCoy’s 5A (Sigma-
aldrich, #M9309), 1 % Penicillin- Streptomycin (Sigma-aldrich, #PO781) and 10 % Fetal Bovine 
Serum (Sigma-aldrich, #F0804)).  
Flasks were incubated and maintained at 37°C and 5% CO2. Every 2-3 day the cells were split by 
washing twice in 10 mL PBS (Lonza, #BE17-512F), trypsinization with 2 mL trypsin (Sigma-aldrich, 
#T3924) for 7 min and resuspending in McCoy’s 5A media. Depending on split ratio, the cell 
suspension was transferred to a culture flask and supplied new growth media. 
Cells were harvested to obtain DNA, RNA and protein. The resuspended cells (see above) were 
transferred to a 15 mL tube and spun down at approximately 1500 rpm for 5 min, to pellet the cells. 
The Media was removed and cells were resuspended in 3 mL PBS. Resuspended cells were 
transferred into three 1.5 mL eppendorf tubes, 1 mL in each tube. Cells were spun down at 13400 
rpm for 5 min and media removed. Pellets were stored at -80°C. 
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3.2 QUANTIFICATION OF NDRG2 MRNA LEVELS 
To evaluate the levels of NDRG2, RNA was isolated from the cancer cell lines, cDNA synthesized 
and assessed by Quantitative Real Time Reverse Transcriptase Polymerase Chain Reaction.   
3.2.1 ISOLATION OF RNA 
RNA isolation was performed with TRI Reagent® Solution (AM9738, Applied Biosystems). Apart 
from centrifugation, every step was done inside a fume hood and everything was cleaned with 
RNaseZAP (Sigma-aldrich, #R2020) before use. 
Cell pellet was collected from -80°C freezer and thawed on ice. Cell pellet was resuspended in 1 mL 
TRI reagent and incubated for 5 min at RT. The sample was centrifuged at 12000 x g, 4°C for 15 min 
and supernatant was transferred to a new tube (working tube). 100 µL of Chloroform ≥99.5 % was 
added and the sample was vortexed ~ 5 sec and incubated at RT for 10 min. 
The sample was centrifuged at 12000 x g, 4°C for 15 min and the aqueous phase (top layer) was 
transferred to a new tube. 500 µL isopropanol was added and the sample was vortexed for 5-20 sec 
and incubated at RT for 5 min. The sample centrifuged at 12000 x g, 4°C for 20 min and supernatant 
was discarded. 1 mL of 75% ethanol was added and the sample was centrifuged at 12000 x g, 4°C for 
20 min. 
The ethanol was carefully removed and the RNA was airdried for max. 10 min. The RNA was added 
50 µL nuclease-free water dissolved by vortexing, put on ice and RNA concentration was measured 
at 260 nm on the NanoDrop® Spectrophotometer ND-1000. RNA was stored at -80°C. 
3.2.2 CDNA SYNTHESIS 
cDNA was prepared from a High-Capacity cDNA Reverse Transcription kit (Applied biosystems, 
#4368814). A total of 10 µL mastermix was prepared for each synthesis reaction as follows; 4.2 µL 
nuclease-free water, 2 µL 10 x RT buffer, 0.8 µL 25 x dNTP Mix (100mM), 2 µL 10 x RT Random 
primers and 1 µL MultiScribeTM Reverse Transcriptase. The mastermix was gently mixed and kept 
on ice until use. For each cDNA synthesis reaction, 10 µL of mastermix was transferred into a 0.2 
mL PCR tube and added 10 µL of diluted RNA (100 ng/ µL). The sample was mixed by pipetting, 
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tube sealed and briefly centrifuged to remove air bubbles. Thermal cycler was set to run; 25°C for 10 
min., 37°C for 120 min., 85°C for 5 sec and paused at 4°C. Prepared cDNA was stored at -20°C. 
3.2.3 QUANTITATIVE REAL TIME REVERSE TRANSCRIPTASE POLYMERASE CHAIN 
REACTION  
Quantitative Real Time Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR) follows the 
principle of regular PCR, but adds an additional layer to the mode of detection of the amplified 
product. There are multiple technologies for qRT-PCR, but in this study SYBR Green technique was 
used. SYBR Green is an intercalating fluorescent dye, which binds double stranded DNA. As the 
target sequence is amplified, the SYBR Green dye will bind and cause a fluorescence signal which is 
detected by a termocycler. This allows quantification of the PCR product in real time, as the 
fluorescence signal “equals” the amount of DNA amplified over time. 
Quantitect® SYBR® Green PCR kit (QIAGEN, #204141) was used for qRT-PCR. For each reaction 
a mastermix was prepared as follows: 5 µL 2 x Quantitect SYBR Green PCR Master mix, 1 µL 
Forward primer, 1 µL Reverse primer and 2 µL nuclease-free water. The mix was added 1 µL of 
template, to a total reaction volume of 10 µL. 
Thermal cycling conditions were; one cycle of 15 min at 95°C for initial enzyme activation, 40 cycles 
of 15 sec at 94°C for denaturation, 30 sec at annealing temperature and 30 sec at 72°C for extension. 
Primers and annealing temperatures can be found in Table 1. 
3.2.3.1 STANDARD CURVE 
When analyzing gene expression by qRT-PCR, one need to consider the efficiency of the PCR 
reaction, that is, the efficiency of the primers. To assess the PCR efficiency, a standard curve can be 
generated by preparing a dilution series of a template, which is known to express the gene of interest. 
By analyzing the slope of the standard curve, the primer efficiency can be evaluated over a range of 
different concentrations and it can be determined at which concentration the primers are expected to 
be efficient and therefore at which concentration an unknown template should be analyzed.  
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The standard curve for NDRG2 expression was prepared from normal human liver cDNA (BD-
Bioscience, 636742). The standard curve for beta-actin expression was prepared from human 
colorectal cancer cell line HCT116. Primers and annealing temperatures can be found in Table 1. 
3.3 DETECTION OF NDRG2 PROTEIN LEVELS 
To detect for NDRG2 protein, the human colon cancer cell line HCT116 was either transfected with; 
A) a plasmid containing a gene for Green fluorescence protein (GFP), which served as a positive 
control for transfection efficiency, as the cells capable of producing the GFP can be visualized under 
a fluorescence microscope, due to the light emission properties of GFP, B) a plasmid containing 
NDRG2, which functioned as a positive control for the presence of NDRG2, but also as control for 
the binding abilities of the antibody, C) an empty plasmid, for the investigation of NDRG2 levels in 
the original cell. Afterwards the protein was extracted and analyzed by western blotting. 
3.3.1 TRANSFECTION OF CELLS 
300.000 HCT116 cells were seeded for each of three wells on a six well plate and allowed to grow 
for one day. On day two, cells were transfected with one of the three different plasmids; pcDNA6-
NDRG2L-V5-HisA, pcDNA6-V5-HisA and pCMV-EGFP. Procedure was performed as follows: 1 
µg plasmid, 2 µL Turbofect transfection reagent (Thermo Scientific, #R0539) and 100 µL McCoy’s 
5A media was mixed and incubated for 20 minutes at RT. The solution was added the correct well 
and cells were allowed to grow for two days. Before harvesting, the transfection efficiency was 
analyzed with a fluorescence microscope camera (Leica DMIRB).  
Cells were harvested by washing once in 1 mL PBS, trypsinizing with 100 µL trypsin for 7 min and 
resuspending in 900 µL McCoy’s 5A media. Pellet was spun down at 13400 rpm for 5 min on a table 
centrifuge and supernatant removed. The pellet was resuspended in 1 mL PBS (to wash of any 
remaining trypsin), spun down at 13400 rpm for 5 min and supernatant removed. Pellet was stored at 
-80°C. 
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3.3.2 WHOLE CELL PROTEIN EXTRACTION 
All steps were done on ice.  
Lysis++ buffer was prepared as follows: 500 µL Lysis buffer*, 1 µL 0.5 M DTT and 1 µL protease 
inhibitor (Sigma-aldrich, #P8340). Cell pellet was collected from -80oC freezer and resuspended in 
50 µL Lysis++ buffer. The sample was incubated on ice for 30 min and spun down at 14000 x g, 4ºC 
for 10 min. Supernatant was transferred to a new tube and pellet discarded. Protein was stored at -80 
oC. 
3.3.3 WESTERN BLOTTING 
Western blotting is a method for detection of protein. Firstly the proteins are separated by 
electrophoresis according to molecular weight and secondly transferred to a membrane by 
electroblotting. The third part is based on the binding abilities of antibodies. A primary antibody is 
designed to bind the protein of interest (the antigen), while a secondary antibody is designed to bind 
the primary antibody. As the secondary antibody is usually to designed possess light emission 
properties, the protein of interest can be detected via a chemiluminescent camera. 
3.3.3.1 PROTEIN MEASUREMENT 
In order to determine the concentration of protein extracted from a cell pellet, a Bradford standard 
curve assay was established. This assay is based on the ability of coomassie brilliant blue dye to 
change color upon binding to protein, which creates an absorbance shift that can be measured 
spectrophotometrically. By adding varying known concentrations of Bovine Serum Albumin (BSA) 
protein, a range in which a specific absorbance corresponds to known protein concentration is created.  
The protein standard curve was established as follows: 1 mL of Bradford* reagent was added; 0 µL, 
1 µL, 2 µL, 4 µL, 6 µL or 8 µL of BSA 1 µg/ µL, respectively. Samples were prepared in duplicates, 
incubated in darkness for 10 min and measured on the spectrophotometer (Biophotometer from 
Eppendorf) at 595 nanometers.   
For the measurement of protein concentration in cell extracts, a blank sample was prepared by adding 
2 µL of Lysis buffer to 1 mL Bradford reagent and for each cell extract, 2 µL of protein was added 
to 1 mL Bradford reagent. The samples were incubated in darkness for 10 min. Before measuring the 
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protein extract samples, the machine was blanked against the blank sample. All samples were 
measured at 595 nanometers. 
3.3.3.2 SEPARATION OF PROTEINS BY GEL ELECTROPHORESIS  
The extracted protein was seperated on a Bis-Tris 4-12 % gel (Life technologies, #NP0322Box). The 
gel was rinsed in deionized water and tape peeled off. Comb was gently removed and wells were 
washed in MilliQ water. The gel was fixed in an XCell SureLock system (Life technologies) and the 
chambers were filled with 1 x Bis-Tris running buffer*. Each of the protein samples were prepared 
for electrophorese as follows: 10-30 µg protein extract, 3.75 µL 4 x Bis-Tris loading buffer (37°C) 
(Life technologies, #NP0007), 1.5 µL DTT 0.5 M and H2O to a total of 15 µL.  
Samples were heated for 10 min at 70°C and meanwhile 10 µL marker (Thermo Scientific, #26616) 
was loaded on the gel. Samples were loaded and the gel was run at 125V for 1-1.5 hours. 
3.3.3.3 TRANSFER OF PROTEINS BY ELECTROBLOTTING  
Before blotting, the blotting pads were soaked in transfer buffer*, the membrane was washed in 96% 
ethanol, rinsed of with MilliQ water and left in it until use and the XCell II blot module (Life 
technologies) was prepared. 
After gel electrophoresis was completed, the gel was separated from the cassette. The blotting pads 
were pressed to remove air bubbles and put one by one into the blot module (approx 3 pieces). Filter 
paper was soaked in transfer buffer and placed on the pads. The gel was placed on top, covered with 
the blotting membrane and filter paper. The layers were held in place and pressed to remove air 
bubbles. Additional blotting pads were pressed and added one by one until the module was full. The 
lid was pressed on and held tightly until the blot module was locked into place in the system. Transfer 
was performed at 25V for ~1 hour.  
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3.3.3.4 ANTIGEN BINDING 
After transfer, the membrane was briefly rinsed with MilliQ water and incubated with 10 mL blocking 
buffer*, at RT on a rocking table for minimum 30 min. The blocking buffer was removed and the 
membrane was washed for 2 x 2 min in PBS-T*. The membrane was separated in two, as the assay 
sought to detect for two different proteins, NDRG2 and the V5-tag. Hereafter each membrane was 
incubated with the respective primary antibody diluted in dilution buffer* on a shaking table 
overnight at 4°C. Antibodies and dilution factors are found in Table 2. 
The next day, each membrane was washed 2 x 10 min in PBS-T and added the secondary antibody 
(see Table 2) diluted in dilution buffer. The membranes were incubated on a shaking table for 
minimum 1 hour at RT. Afterwards the membranes were washed 4 x 10 min in PBS-T. 
3.3.3.5 PROTEIN DETECTION AND MEMBRANE STRIPPING 
To develop photos, the blots were incubated in darksness with 2 mL of SuperSignal® West Dura 
reagent mix (Thermo Scientific, #34076) for 5 min. To detect for proteins, the blots were 
photographed with the BioSpectrum® Imaging System from UVP, which detects the UV emission 
from the secondary antibody. 
After photography, the membranes were stripped of antibodies by washing the membranes in MilliQ 
water for 5 min, in 0.2 M NaOH for 5 min and in MilliQ for 5 x 2 min.  
Next, the membranes were blotted for beta-actin protein detection, to confirm loading accuracy and 
the presence of protein in all protein extract samples, according to the procedure described for antigen 
binding. See Table 2 for antibodies and dilutions. 
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3.4 EVALUATION OF NDRG2 PROMOTER METHYLATION STATUS 
To examine the methylation status of the NDRG2 promoter in the cancer cell lines HCT116 and 
SW480, the DNA was isolated, treated with bisulfite and amplified by Methylation Specific PCR 
(MSP). The result was analyzed by gel electrophoresis, followed by sequencing of the MSP product.  
3.4.1 DNA ISOLATION 
Cell pellet used, was either newly harvested cells or pellet collected from -80°C freezer and thawed 
on ice. Pellet was resuspended in 270 µL TENS buffer* and 15 µL Proteinase K (20 mg/mL) (sigma-
aldrich, #P2308). The sample was incubated at 55°C overnight. The next day, the sample was 
collected and put on the bench until room temperature was reached. The sample was added 30 µL 
3M NaAC and 700 µL 96% ethanol and mixed by pipetting. Sample was centrifuged at 13400 rpm 
for 15 min, supernatant removed and saved in case DNA was not detectable. Pellet was washed with 
600 µL 80% ethanol at RT for 5 min. Tube were flipped over 2-3 times. Sample was centrifuged at 
13400 rpm for 15 min and supernatant removed and saved. The DNA was mixed with 1000 µL TE-
buffer* and incubated at 55°C for 3 hours. The DNA was put at 4°C, overnight and DNA 
concentration was measured at 260 nm on NanoDrop machine the following day. DNA was stored 
4°C. 
3.4.2 IN VITRO METHYLATION OF GENOMIC DNA 
To assess the methylation status of the NDRG2 promoter in the cell lines, a positive control in which 
the DNA were fully methylated, was prepared. Fully methylated DNA can be created by treating 
Genomic DNA with CpG Methyltransferase, M.SssI, which methylates all the cytosines contained in 
a CpG context.  
To prepare fully methylated DNA, reagents were mix in the following order: 10 µL nuclease-free 
water, 2 µL 10X NEBuffer 2 (Biolabs, #B7002S), 2 µL SAM (1600µM) (Biolabs, #B9003S), 5 µL 
Genomic DNA (200 ng/ µL) (Roche, #11691112001) and 1 µL SssI methylase (4 U/ µL) (Biolabs, 
#M0226S). All reagents were mixed by pipetting up and down 10 times. The samples was incubated 
at 37°C for one hour or overnight. The reaction was stopped by heating at 65°C for 20 minutes. 
Methylated DNA was stored at 4°C for immediate use or at -20°C for long time storage. 
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3.4.3 BISULFITE CONVERSION 
Bisulfite modification of DNA is the most commonly used technique for assessment of methylation 
patterns within a DNA sample. The technique uses sodium bisulfite to convert all unmethylated 
cytosines to uracil, leaving methylated cytosines intact, see Figure 15. Upon treatment, the 
methylation status can be analyzed, for example methylation specific poly chain reaction (MSP) or 
bisulfite sequencing. 
 
 
Figure 15 - Overview of methylated DNA and unmethylated DNA upon bisulfite treatment and Methylation Specific 
Polymerase Chain Reaction (MSP). 
The treatment was performed with BisulFlashTM DNA Modification Kit (Epigentek, P-1026) 
according to the supplied protocol. 
Samples modified were; In vitro methylated Genomic DNA, Genomic DNA, HCT116 DNA and 
SW480 DNA. Input DNA amount was 200 ng per reaction. 
3.4.4 METHYLATION SPECIFIC POLYMERASE CHAIN REACTION 
Methylation Specific Polymerase Chain reaction (MSP) uses the principles of regular PCR, however 
in this technique, the DNA is modified with sodium bisulfite, as described above. The primer sets are 
designed to recognize either methylated DNA, having the original cytosines, or unmethylated DNA, 
having thymines which replaces the uracils during the PCR reaction, see Figure 15. 
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MSP was performed with Maxima Hot Start PCR Master Mix (2X) (Thermo Scientific, #K1051). For 
each reaction; 7.5 µL Maxima Hot Start PCR Master Mix (2X), 4.5 µL nuclease-free water, 1 µL 
Forward primer, 1 µL Reverse primer and 1 µL template was mixed by vortexing and spun down. 
Thermal cycling conditions were; one cycle of 4 min at 95°C for initial denaturation and enzyme 
activation, 40 cycles of 30 sec at 95°C for denaturation, 30 sec at annealing temperature and 30 sec 
at 72°C for extension, and one cycle of 5 min at 72°C for final extension. Primers and annealing 
temperatures can be found in Table 1. 
The amplified MSP product was separated by electrophoresis on a 1 % agarose gel supplied with 4 
mg ethidium bromide and detected by the High Performance UV Transilluminator (UVP). 
3.4.5 METHYLATION SPECIFIC SEQUENCING 
Following MSP, the product was isolated, to analyze the amplified sequence by methylation specific 
sequencing. The methylation specific sequencing was perform by Eurofins MWG Operon and the 
primers used, were the same as for MSP, see Table 1. 
3.4.5.1 PURIFICATION OF PCR PRODUCT  
The MSP product was isolated from the agarose gel with High Pure PCR product purification kit 
(Roche, #11732676001). The gel part containing the MSP product was cut out and weighed. For each 
100 mg, 300 µL binding buffer was added and the sample was vortexed to dissolve the gel. The 
sample was incubated at 56ºC with vigorous shaking for 10 min, to completely dissolve the gel. 
For each 100 mg weigh, 150 µL isopropanol was added and the sample was thoroughly vortexed. 
The sample was filtered and centrifuged at 13400 rpm. The flowthough was discarded and filter was 
added 500 µL Wash buffer. The sample was centrifuged for 1 min at 13400 rpm and the flowthough 
was discarded. The sample was added 200 µL Wash buffer, centrifuged for 1 min at 13400 rpm, the 
flowthough discarded and centrifuged again. The filter was transferred to a new tube, added 25 µL 
TE-buffer and incubated at room temperature for 3-5 min. The sample was spun down for 1 min at 
13400 rpm and the DNA concentration was measured on the NanoDrop machine. 
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3.5 EVALUATION OF NDRG2 LEVELS UPON DEMETHYLATION 
The demethylating agent, 5-azacytidine, is a cytidine analouge which can be incorporated into DNA 
and inhibit DNA methyltransferase activity. Upon treatment, the effects can be accessed by for 
example qRT-PCR or MSP. By comparing mRNA levels obtained by qRT-PCR of untreated vs. 
treated cells, the quantity of methylation can be indirectly visualized.  
40.000 HCT116 cells were seeded per well in a 6 well plate (10 cm2) and allowed to grow overnight 
before treatment. For each experiment a fresh 5-azacytidine (Sigma-aldrich, A2385) stock solution 
was prepared according to instructions (~1.2 mg/10 mL). Cells were treated with a solution of 1 µM 
5-azacytidine, which has been shown to be sufficient for hypomethylation in HCT116 cells 
(Schneider-Stock et al. 2005). The solution of 1 µM 5-azacytidine in growth media was prepared 
freshly from stock solution for each media replacement, every second day. Cells were treated for 24-
, 48-, 72-, 96-, 120 and 144 hours, after which they were harvested and stored as previously described 
for transfected cells, see section 3.3.1. 
The effects of 5-azacytidine treatment was analyzed by qRT-PCR according to the procedure 
described in section 3.2.3, with the primers and annealing temperatures supplied in Table 1. 
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3.6 DETECTION OF PROTEINS INTERACTING WITH NDRG2  
To examine if specific proteins were interacting with the promoter of NDRG2, proteins were cross-
linked to DNA in HCT116 colon cancer cell line and precipitated by Chromatin immunoprecipitation 
(ChIP). ChIP results were analyzed be Quantitative Polymerase Chain Reaction (qPCR) according to 
the procedure described for Quatitative real time Reverse Transcriptase Poly Chain Reaction (qRT-
PCR) in section 3.2.3, with the primers and annealing temperatures supplied in Table 1. 
3.6.1 CROSS-LINKING, CELL HARVESTING AND DNA ISOLATION  
Cross-linking between proteins and DNA can be induced by formaldehyde and the reaction 
terminated by glycine. Cross-linking and cell harvesting was performed according to the Abcam® 
protocol; A Beginner’s Guide to ChIP. The DNA was isolated and measured according to the 
procedure described in section 3.4.1. 
3.6.2 CHROMATIN IMMUNOPRECIPITATION 
The Chromatin immunoprecipitation (ChIP) reaction was performed as an optimized version of the 
standalone protocol supplied by Epigentek ChromaFlashTM One-Step ChIP Kit (Epigentek, P-2025). 
To shear the DNA into smaller fragments which are more soluble and therefore more accessible for 
antibody binding, DNA was kept on ice and sonicated for 3 x 15 seconds with intermediate pauses of 
45 seconds on a sonication machine (Sonics & Materials).  
Before immunoprecipitation, the sheared DNA was pre-cleared with Sepharose G (Amersham 
Biosciences, #17-6002-35) to reduce non-specific binding in the ChIP reaction. Procedure was 
performed as follows: 20 µL Sepharose G for 300 µL DNA was added and the sample was incubated 
for two hours at 4ºC and 1400 rpm (to ensure that the sample was mixed). To pellet the sepharose, 
the sample was centrifuged for three minutes at 2000 rpm and supernatant was transferred to a new 
tube. 
According to protocol, each immunoprecipitation was performed on 50 µL DNA solution, 
corresponding to 7.2 µg DNA, with 60 µL ChIP Buffer and 0.8 µg antibody. Table 3 lists the 
antibodies used. The samples were incubated overnight at 4ºC and 1400 rpm. The next day, the 
samples were added 20 µL of sepharose G and incubated for two hours at 4ºC and 1400 rpm. Samples 
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were spun down at 3000 rpm for two minutes and supernatant was carefully removed. The pellet was 
washed four times in 1 x Wash Buffer according to protocol, but was spun down at 2000 rpm for 3 
minutes between washes. 
The DNA was de-crosslinked by adding 39 µL DNA Release Buffer and incubating the DNA sample 
at 65ºC overnight. To digest the proteins, each DNA sample was added 1 µL of Proteinase K (10 
mg/mL) and incubated for two hours at 45 ºC and 1400 rpm. Proteinase K was inactivated by 
incubating the samples at 95 ºC for one minute. DNA was either used immediately or store at -20 ºC. 
3.7 STATISTICAL ANALYSIS 
When studying a difference between sample groups, for example treated vs. untreated, it is important 
to realize that any observed difference between the groups could merely be a result of a normal 
distribution within the samples. Therefore, to analyze if any observed difference between two sample 
groups is truly a significant result, of for example some treatment, a statistical analysis can be applied 
to calculate the probability that the samples within the two groups are in fact different.  
The student’s t-test is one of the most commonly used techniques for testing if samples within two 
groups are significantly different and was used it this thesis.  
All t-tests were performed using a two tailed, two-sample equal variance test in excel. The level of 
statistical significance was set to p <0.05.
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Table 1: Primer sequences and annealing temperatures (TM) for Methylaion Specific Polymerase Chain Reaction (MSP), Quantitative Real Time Reverse Transcriptase 
Polymerase Chain Reaction (qRT-PCR) and Quantitative Real Time Polymerase Chain Reaction (qPCR). The primers denoted with an asterisk (*) are from Piepoli et 
al. 2009. 
Gene 
 
Forward primer 
5’  3’ 
 
Reverse primer 
5’  3’ 
 
TM 
ºC 
 
Size 
bp 
MSP primers 
Cdk4 TTTAGGATGGTAATTGGTTTTGTT ATCTCCAATTACCAACAACAACTATA 55 204 
Met-NDRG2* AGAGGTATTAGGATTTTGGGTACG GCTAAAAAAACGAAAATCTCGC 60 123 
Unmet-NDRG2* GGTAAATTTATTTGGGTATTGA CAAAAACAAAATTAACCCTACAAA 55 210 
qRT-PCR primers 
Beta-actin TCACCCACACTGTGCCCCATC CAGCGGAACCGCTCATTGCCAATGG 60  
NDRG2 GCTACAACAACCGCCGAGAC ACAGGCGAGTCATGCAGGA 55  
qPCR primers 
MYC CCAGAGGAGGAACGAGCTAA TTGGACGGACAGGATGTATG 60  
NDRG2 CTTGAGGCATTGACCCCAGAG CTCTTTGCTGCGTCCCGAC 60  
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Table 2: Antibodies and dilutions used for Western Blotting. 
Antigene 
Molecular weight 
(kDa) 
Primary antibody / Secondary Antibody Dilution Supplier 
NDRG2 41 
Goat polyclonal IgG / 
Donkey IgG-HRP 
1:5000 / 1:10000 
Santa-cruz Biotechnology, 
#Sc-19468    /    #Sc-2056 
V5 ~14 + 41(NDRG2) 
Rabbit monoclonal IgG / 
Goat IgG-HRP 
1:5000 
Sigma-aldrich, #V8137    / 
Pierce, #1858415 
Beta-actin 42 
Mouse monoclonal IgG / 
Goat IgG-HRP 
1:10000 
Sigma-aldrich, #A5441   / 
Pierce,  #1858413 
 
Table 3: Antibodies used for Chromatin immunoprecipitation. 
Antigen Antibody Supplier 
Anti-GFP Monoclonal mouse IgG Sigma-aldrich, #G1546 
RNA polymerase II Information not supplied by firm Epigentek,  #P-2015 
MYC Monoclonal mouse IgG Abcam,  #ab56 
MeCP2 Polyclonal rabbit IgG Abcam,  #ab2828 
 Page 52 of 75 
 
Blocking buffer (5%): 
20 mL PBS-T  
1 g blocker (GE healthcare, #RPN2125V)  
 
Bradford reagent: 
 200 mg of Coomassie Brilliant Blue 
(AppliChem, #A3480,0010)  
100 mL 96% ethanol 
 200 mL 85% phosphoric acid. 
MilliQ water until 2 liters 
Filtered and stored dark 
 
Dilution buffer (2.5%): 
20 mL PBS-T  
0.5 g blocker (GE healthcare, #RPN2125V) 
 
Lysis buffer:  
200 µL 1 M Hepes (pH 7,9)  
15 µL 1 M MgCl2 
4.2 mL1 M NaCl 
2.9 mL 87% glycerol 
2.7 mL MilliQ water 
Store at 4ºC 
 
PBS 10X (pH 7.3): 
1,4M NaCl 
27mM KCl 
101mM Na2HPO4 
18mM KH2PO4 
 
PBS-T (0.1%): 
1 liter 1X PBS  
1 mL Tween-20 (Sigma-aldrich, #P2287)  
 
Running Buffer:  
50mL 20X NuPAGE MOPS SDS (Life 
technologies, #NP0001) 
950 mL MilliQ water 
 
TE-buffer: 
10mM TrisCl pH 8.0 
1mM EDTA 
TENS-buffer: 
100mM TrisCl pH 8.5  
5mM EDTA 
200mM NaCl  
0.2% SDS (stock ≥ 99%) 
 
Transfer buffer:  
50 mL 20X NuPAGE Transfer buffer (Life 
technologies, #NP0006-1) 
 200 mL of 96% ethanol  
750 mL MilliQ water 
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4 RESULTS  
4.1 NDRG2 LEVELS 
NDRG2 has been reported down-regulated for several cancers and that expression levels correlate 
inversely to clinical stages of various tumors (Yao et al. 2008; Lorentzen & Mitchelmore 2012).        
To estimate the expression level of NDRG2 in the human colon cancer cell lines, HCT116 and 
SW480, cDNA was synthesized and analysed by qRT-PCR.  
Normal human liver cells have been reported to express moderate levels of NDRG2 (Deng et al. 2003) 
and were used as positive control. All expression levels were normalized to beta-actin and as can be 
seen from Figure 16, both HCT116 and SW480 express much lower levels of NDRG2, when 
compared to the expression level in normal human liver cells.  
 
 
Figure 16 - NDRG2 mRNA expression normalized to beta-actin for normal liver, HCT116 and SW480 cancer cell lines. 
Columns represent mean value of ΔCt for two independent experiments and standard errors are not displayed, as they are 
too small to be visualized. 
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 The NDRG2 expression in the cancer cell 
lines, HCT116 and SW480, was further 
analyzed by student’s t-test, to estimate if the 
observed down-regulation was significant. A 
p-value of ≤ 0.05 is considered to be significant 
and as can be seen from Table 4, the down-
regulation was very significant. 
Table 4 – p-values for student’s t-test comparing 
NDRG2 expression levels in HCT116 and SW480 
cancer cell lines to NDRG2 expression levels in normal 
liver.
  
4.2 NDRG2 PROTEIN LEVELS 
Decreased levels of the NDRG2 protein have been observed for a number for diffenrent cancers and 
cancer cell lines. Although very little is known about the biological function of the NDRG2 protein, 
studies have shown that re-expression of NDRG2 can reduce growth in cancer cell lines and that 
NDRG2 expression correlates positively with the differential state of tumor tissue (Kim et al. 2009). 
To identify if NDRG2 protein levels were effected by the down-regulation observed at NDRG2 level, 
protein extract from HCT116 cell line was assessed by Western Blotting. The cancer cell line SW480 
was not included in this experiment, due to some difficulties in evaluation of methylation status, see 
paragraph 4.3.  
NDRG2 protein levels were evaluated in HCT116 cells transfected with the empty plasmid, pcDNA6-
V5-HisA plasmid. A positive control for NDRG2 expression was established by transfecting HCT116 
cells with pcDNA6-NDRG2L-V5-HisA plasmid. As this plasmid contains the long version of 
NDRG2 (NDRG2L), it is expected to generate a protein of approximately 41 kiloDalton (kDa). 
Further, the plasmid is contructed with a V5- and histidine- tag coupled to the NDRG2L. These tags 
can additionally be targeted by antibodies and thereby serve as positive controls for the pressence of 
NDRG2. 
The protein extractes were analyzed with antibodies targeting the NDRG2 protein and the two 
positive controls, the V5-tag  and beta-actin. Because the V5-tag, as mentioned, is coupled to 
Cell line p-value     
HCT116 4.7 x 10-8 
SW480 1.5 x 10-6 
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NDRG2L, it functioned as a positive control for the pressence of NDRG2 and was expected to be 
detectable at 55 kDa, corresponding to the 41 kDa from NDRG2L+ ~14 kDa from the V5-tag. The 
beta-actin protein  (42 kDa) was used to test for loading accuracy and the overall pressence of protein 
in the protein extracts. 
For the immunoblot with NDRG2 antibody an intens band was observed between 40 and 50 kDa for 
HCT116 cells transfected with pcDNA6-NDRG2L-V5-HisA plasmid, and no band was observed for 
pcDNA6-V5-HisA transfected cells, see top picture Figure 17A.  
 
 
Figure 17 - NDRG2 protein level analysis by Western blotting for HCT116 transfected with pcDNA6-NDRG2L-V5 
plasmid and HCT116 transfected with pcDNA6-V5-HisA plasmid. A) Top picture -Antibody targeting NDRG2 / Bottom 
picture – Antibody targeting Beta-actin. B) Top picture -Antibody targeting V5-tag / Bottom picture – Antibody targeting 
Beta-actin. 
Further, when blotted with the V5-tag antibody, a clear band was oberserved at approximately 55 
kDa for pcDNA6-NDRG2L-V5-HisA transfected cells. No band was observed for the pcDNA6-V5-
HisA transfected cells, see top picture Figure 17B.  
For all samples blotted with the beta-actin antibody, a band of approximately equally intensity was 
observed at around 42 kDa, see bottom pictures Figure 17A and Figure 17B. 
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4.3 METHYLATION STATUS OF THE NDRG2 PROMOTER REGION 
The observed down-regulation of NDRG2 expression in many cancers, have been reported to 
correlate with the methylation status at the promoter region (Piepoli et al. 2009; Feng et al. 2011). 
Therefore, as NDRG2 expression was shown to be down-regulated in cancer cell lines HCT116 and 
SW480, the methylation status of the NDRG2 promoter was examined.  
DNA from cancer cell lines HCT116 and SW480, was tested by Methylation Specific polymerase 
Chain Reaction (MSP) with specific primers for either methylated DNA, expected to generate a PCR 
product of 123 base pairs (bp) or unmethylated DNA, 210 bp. Additional samples included were; in 
vitro methylated genomic DNA (SssI) as a positive control of DNA methylation, genomic DNA as a 
negative control of DNA methylation and nuclease-free water (H2O) as an overall control for 
contamination.  
When analyzing the NDRG2 promoter with primers specific for methylated DNA, the positive control 
(SssI) and both the HCT116 and SW480 cancer cell line, was observed to be methylated, see Figure 
18A. Further, the samples were not amplified using primers specific for unmethylated DNA, see 
Figure 18B. The negative control, genomic DNA, was not amplified by primers specific for 
methylated DNA, see Figure 18A, but was observed to be unmethylated at the NDRG2 promoter, see 
Figure 18B. None of the primers amplified the H2O sample. 
 
 
 
Figure 18 - Methylation status of the NDRG2 promoter, determined by Methylation Specific Polymerase Chain Reaction 
(MSP) for; in vitro methylated genomic DNA (SssI), human colorectal cancer cell line HCT116, human colon 
adenocarcinoma cell line SW480, Genomic DNA and nuclease-free water (H2O) . A) Results from MSP with primers 
specific for methylated DNA, 123 bp. B) Results from MSP with primers specific for unmethylated DNA, 210 bp. 
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The MSP product was further analyzed by sequencing and data obtained showed that Genomic DNA 
was partly unmethylated at the region analyzed, see Figure 19A. For the positive control SssI and the 
cell lines HCT116 and SW480, sequencing data revealed that the region analyzed was fully 
methylated, see Figure 19B. 
 
In the attempt to analyze the methylation status of the NDRG2 promoter, MSP was performed 
multiple times, showing that results for SssI, HCT116 and genomic DNA were replicative. However, 
some results for SW480 showed irregularities (data not shown) and this cell line was therefore not 
used for analyzing NDRG2 protein levels, experiments with restoration of NDRG2 expression or 
investigation of promoter binding by specific proteins.  
 
 
Figure 19 – Methylatation status of the NDRG2 promoter, analyzed by sequencing. Empty circles denotes unmethylated 
CpG’s, black circles represents methylated CpG’s, ND denotes Not Determined CpG’s. A) Results for Genomic DNA, 
analyzed with primers for unmethylated DNA. B) Results for SssI, HCT116 and SW480, analyzed with primers for 
methylated DNA. 
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4.4 NDRG2 LEVELS AFTER 5-AZACYTIDINE TREATMENT 
The levels of NDRG2 was shown to be down-regulated for HCT116 cancer cells, when compared to 
expression in normal liver cells. Further, results from MSP showed that the promoter region of 
NDRG2 was methylated. To investigate if these observations could be correlating, HCT116 cells were 
treated with the demethylating agent 5-azacytidine, to see if reversal of the methylation status could 
restore NDRG2 expression over time. 
The HCT116 cells were treated with 1 µM of 5-azacytidine in growth media for 0-, 24-, 48-, 72-, 96-
, 120-, and 144 hours. Effects on NDRG2 were analyzed by qRT-PCR and normalized to beta-actin. 
As can be seen from Figure 20, 5-azacytidine treatment was able to restore NDRG2 expression, when 
compared to untreated cells, after only 24 hours of treatment and caused continuous restored 
expression at all times measured. 
 
 
Figure 20 - Fold increase of NDRG2 mRNA normalized to beta-actin for HCT116 cells treated with 5-azacytidine. Cancer 
cell line HCT116 was treated with 1 µM of 5-azacytidine in growth media for 0-, 24-, 48-, 72-, 96-, 120-, and 144 hours. 
Columns represent the mean values of ΔΔCt for normalized fold increase of NDRG2 mRNA in treated cells relative to 
untreated cells for three independent experiments. Error bars represent standard deviation. 
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To analyse if the expression of NDRG2 was significantly altered by treatment with 5-azacytidine, a 
student t-test was applied to compare the fold increase of NDRG2 in treated cells to NDRG2 level in 
untreated cells. A p-value of ≤ 0.05 is considered to be significant.  
A significant difference in NDRG2 expression was observed for cells treated with 5-azacytidine for 
48-, 72- and 120 hours, see Table 5. 
 
 
 
 
 
 
 
Table 5 – p-values for student t-test comparing the NDRG2 expression level in 5-azacytidine treated HCT116 cells to 
levels in untreated HCT116 cells. 
 
 
 
 
 
 
 
 
 
 
 
Hours of 5-azacytidine treatment p-value 
24 hours 0.38 
48 hours 0.00014 
72 hours 0.00012 
96 hours 0.06189 
120 hours 0.00954 
144 hours 0.20519 
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4.5 PROTEINS INTERACTION WITH NDRG2 PROMOTER 
The regulation of genes can be performed at various levels. At gene level, the binding of specific 
transcription factors may facilitate or block transcription. Further, binding of epigenetic factors, like 
Methyl-CpG binding domain proteins (MBDs), to methylated CpG-islands have been reported to 
mediate transcriptional repression (Ballestar & Wolffe 2001). The down-regulation of NDRG2 
observed for various cancer may therefore, in addition to DNA methylation, also be a consequence 
of transcriptional repression mediated by either transcription factors or methyl-CpG binding domain 
proteins. The transcription factor MYC has previously been reported to interact with NDRG2 and 
cause repression (Zhang et al. 2006). The MBD, MeCP2, have been shown to bind tightly to 
methylated DNA and cause transcriptional repression (Tost 2008).   
To identify if MYC and MeCP2 were able to the methylated promoter of NDRG2, DNA from the 
cancer cell line HCT116 was analyzed by chromatin immunoprecipitation (ChIP). The HCT116 cell 
line has been reported to expressed MYC (Okuyama et al. 2010). Antibodies used were targeting 
Green fluorescent protein (GFP), RNA polymerase II, MYC and MeCP2. Afterwards the DNA was 
analyzed by qPCR to determine the abundance for NDRG2 in the precipitated DNA.  
The GFP-antibody was included as a negative control, but also served for normalization of data. As 
GFP originally was isolated from the jellyfish Aequorea Victoria, the HCT116 cells were not 
expected to express GFP and therefore any DNA precipitated with the GFP-antibody represents non-
specific binding or background signals. The antibody targeting RNA polymerase II was included as 
a positive control for both the ChIP procedure and qPCR reaction. As RNA polymerase II is necessary 
for transcription, this protein is expected to bind to genes undergoing transcription, for instance MYC. 
The DNA precipitated with the RNA polymerase II antibody, was analyzed for MYC abundance and 
normalized to Anti-GFP signal. As can be seen from Figure 21, DNA precipitated with RNA 
polymerase II antibody had enriched MYC levels.  
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Figure 21 - qPCR analysis of chromatin immunopreipitation (ChIP) in HCT116 cancer cell line. Cells were 
immunoprecipitated with antibodies targeting; Green fluorescent protein (Anti-GFP), RNA polymerase II (RNA pol), 
MYC and MecCP2. Columns represents fold enrichment normalized to Anti-GFP signal. RNA pol ChIP DNA was 
analyzed for Myc abundance, MYC and MeCP2 was analyzed for NDRG2 abundance. 
The levels of normalized NDRG2 was found to be enriched DNA precipitated with the MYC 
antibody, see Figure 21, but no enrichment was observed for DNA precipitated with MeCP2, see 
Figure 21.  
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5 DISCUSSION 
The fact that cancer is a leading cause of death and that death rates are predicted to rise (WHO 2013), 
demonstrates the importance of studying the molecular mechanisms driving the process of 
tumorigenesis, in order to elucidate how these events may be prevented or treated. One of the 
mechanisms recognized to play an important role in the generation of cancer, is that of epigenetic 
gene regulation. Epigenetic alterations have been observed for several cancers and have been shown 
causative of both oncogene activation and silencing of tumor suppressors (Sharma et al. 2010). As 
these alterations are potentially reversible, they represent a promising therapeutic target and have 
therefore been studied intensively during the last decades (Furney et al. 2012; Hatzimichael & Crook 
2013). One of the recently accepted tumor suppressor genes, NDRG2, has been reported down-
regulated in several cancers and to be subjected to aberrant epigenetic gene regulation. As the down-
regulated expression profile has been demonstrated to relate to advanced clinical stage and poor 
overall survival (Shu-jun Li et al. 2013; Cao et al. 2013), this gene may be of both diagnostic, 
prognostic and therapeutic relevance and therefore the study of the mechanisms driving the NDRG2 
down-regulation has gained much attention. Thus, to contribute to the elucidation and establishment 
of how NDRG2 can be down-regulated in cancer, the expression profile and some of the epigenetic 
mechanisms, which have been reported to correlate with the down-regulation of NDRG2, were 
investigated using the human cancer cell lines, HCT116 and SW480, as model systems.  
The expression profile of NDRG2 was analyzed for both cancer cell lines and showed that, when 
compared to expression levels in normal human liver, the NDRG2 expression in both cell lines were 
about 1/100 of the NDRG2 expression levels observed for normal liver. Further, the significance of 
the down-regulated expression was shown to be; HCT116, p = 4.7 x 10-8, SW480, p = 1.5 x 10-6, 
which demonstrates that for both cancer cell lines, the observed NDRG2 expression level is 
significantly different from that of liver. Taken together, these results show that in the cancer cell 
lines, the expression of NDRG2 is highly down-regulated, when compared to expression levels in 
liver. However, since the biological functions of genes are generally performed by the products, it is 
the existence or absent of proteins which really matters. Thus, in order to establish, if the observed 
down-regulation at mRNA level also entailed down-regulation at protein level, whole cell protein 
extract from the HCT116 cancer cell line was analyzed by western blotting. Before the analysis the 
cells were transfected with either an empty plasmid, to see if NDRG2 protein was detectable in the 
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original cancer cells or a plasmid containing NDRG2 as a positive control, to ensure that the antibody 
in fact was capable of binding NDRG2 protein. 
The analysis revealed that the NDRG2 protein was not detectable for the cells containing the empty 
plasmid, but could be detected for the cells transfected with the plasmid containing NDRG2. This 
observation demonstrates that the antibody was capable of binding to the NDRG2 protein and that 
the protein was not subjected to rapid degradation. Therefore, the HCT116 cancer cells are either 
unable to produce the NDRG2 protein or the production is so markedly reduced, that the protein is 
undetectable by the antibody. However, when considering the significantly down-regulated 
expression of NDRG2, this signifies that the HCT116 cancer cells are in fact unable to produce the 
NDRG2 protein due to a significant down-regulation at mRNA level. Further, this observation is in 
line with results obtained by other researchers (Feng et al. 2011; Shu-jun Li et al. 2013).  
In order to elucidate if the observed down-regulation of NDRG2, might be caused by abnormalities 
in epigenetic mechanisms, the cancer cell lines were analyzed by MSP and sequencing, to reveal if 
the NDRG2 promoter was aberrantly methylated. Both MSP and sequencing results revealed that for 
both cell lines, the NDRG2 promoter was excessively methylated. However, some difficulties were 
also experienced with the SW480 cell line, in which the NDRG2 were not always amplified by the 
methylation specific primers. This was however not regarded as reflecting the methylation status, as 
this cell line was previously analyzed in the laboratory and was confirmed to be methylated at the 
NDRG2 promoter (personal communication by Anders Blomkild Lorentzen). Thus the conflicting 
results were merely thought to be owing to some technical difficulties, which could be caused by the 
primers or might be human errors. 
As it was observed that the NDRG2 promoter was methylated in HCT116 cancer cells and that this 
methylation status correlated to a significant down-regulation of NDRG2, these cells were treated 
with the demethylating agent, 5-azacytidine, to establish if reversing the methylation status could 
reintroduce NDRG2 expression. By treating the cells with 1 µM 5-azacytidine for 24- to 144 hours, 
it was proved that 5-azacytidine could in fact reestablish NDRG2 expression. NDRG2 was shown to 
be up-regulated, compared to untreated cells, after only 24 hours of treatment and although this up-
regulation was not significant, a very significant up-regulation was observed at 48- and 72 hours of 
treatment. Additionally, it was shown, that the expression was continuously up-regulated at all time-
points measured. The observation that demethylating agents can reestablish NDRG2 expression is in 
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line with findings by other researchers (Piepoli et al. 2009; Chang et al. 2013) and provides hope for 
the usage of demethylation agents as a therapeutic option in cancer treatment. 
The down-regulation of NDRG2 was further analyzed, as the repression might also be caused by the 
binding of transcription factors or methyl-binding proteins. The ChIP analysis showed that MYC is 
capable of binding NDRG2, but that the methyl-binding protein, MeCP2, is not. This observation 
could mean that, in the HCT116 cancer cells, MYC is part of the system repressing NDRG2 
expression. However, even though MYC previously has been shown to interact with NDRG2, it has 
also been shown that NDRG2 is not regulated by this transcription factor. There is therefore a need 
for further investigation before the role of MYC in NDRG2 repression can be fully established. 
The fact that MeCP2 was not shown to bind to NDRG2, could simply mean that this protein is not 
involved in the repression. However, as it was not investigated if these cells did in fact express the 
protein, it could also reflect the gene expression profile of the HCT116 cancer cells. Additionally, 
there was no positive control for the binding abilities of the MeCP2 antibody and therefore the result 
could also be caused by the antibody simply not being capable of binding the MeCP2 protein. Further, 
this result might also reflect that the MeCP2 protein is somehow blocked through its interaction with 
co-repressor complexes, histone deacetylases, histone methylases or the ATP-dependent chromatin 
remodeling complexes, and therefore the antibody is unable to bind. Therefore, based on the results 
obtained by ChIP in this thesis, it cannot be rejected that MeCP2 does in fact bind NDRG2 and 
contributes to the repressional state in cancer. However, this will have to be studied further in order 
to be established. 
Although the precise biological function of NDRG2 is still not clarified, the reduced expression levels 
observed in cancer cells, clearly implicates NDRG2 as a player in tumorigenesis. The fact that 
NDRG2 is observed to down-regulated at mRNA and protein level in both cancer cell lines 
investigated in this thesis and that similar results have been obtained for other cancer cell lines and 
cancer tissues (Kim et al. 2009; Lorentzen et al. 2011; Cao et al. 2013), indicates that the down-
regulation is not just random. Thus, it could be that NDRG2 has the potential to become a new 
diagnostic biomarker. It is however, still not established if the down-regulation of NDRG2 is a 
common trait of cancer cells or if it only applies to specific cancer types. Therefore, in order to 
evaluate the potential of NDRG2 as a diagnostic biomarker, further experiments will have to be 
conducted, to establish if all cancers share this down-regulation or if it is a cancer specific trait. 
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The down-regulation of NDRG2 has also been linked to an advanced clinical cancer stage and to poor 
overall survival of patients (Chu et al. 2011; Shu-jun Li et al. 2013; Cao et al. 2013). Therefore, it is 
possible that NDRG2 might be able to function as a biomarker for cancer prognosis. However, as 
also stated for the potential use of NDRG2 as a diagnostic biomarker, this will require that it is 
elucidated precisely in which cancer types NDRG2 is down-regulated. Further, it will also be 
necessary to establish the precise clinical outcome of NDRG2 down-regulation, in order for NDRG2 
to be a reliable prognostic marker. 
The classification of NDRG2 as a tumor-suppressor gene is, amongst other things, based on its ability 
to inhibit the growth and migration of cancer cells (Gao et al. 2011; Zheng et al. 2011; Ruixiao Li et 
al. 2013). Accordingly, as NDRG2 is observed to be down-regulation in cancer cells, it could be 
speculated if restoring the expression might be able to better clinical outcome of patients. Although 
this ability is still not elucidated, it still provides hope for the use of NDRG2 as a therapeutic target, 
as I and others have reported that the NDRG2 down-regulation in cancer is caused by promoter 
methylation and that treatment with demethylating agents can restore the expression (Tepel et al. 
2008; Piepoli et al. 2009; Feng et al. 2011).  
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6 CONCLUSION AND FURTHER DIRECTIONS 
The exact biological function of NDRG2 still needs to be clarified, but evidence is clearly pointing 
to, that the function relates to some kind of maintenance of normal cellular identity. Therefore, 
clarifying the connection between expression levels in normal and abnormal cells, in addition to its 
regulation, will be of great importance in elucidating the implication and function of this gene.  
In this thesis, using the human cancer cell lines, HCT116 and SW480, as a model system, it was 
shown that NDRG2 is significantly down-regulated in both cancer cell lines, when compared to 
expression levels in normal human liver and that this expression profile correlated with an 
undetectable level of NDRG2 protein in the HCT116 cancer cell line. Further, it was observed that 
the NDRG2 promoter region was excessively methylated in both cancer cell lines, when compared to 
the methylation status of normal human genomic DNA. These observations taken together, indicates 
that the expression profile observed for the cancer cell lines is caused by gene repression, due to 
excessive DNA methylation at the promoter region. This correlation was additionally analyzed and it 
was confirmed that the reduced levels of NDRG2 in the HCT116 cell line could be restored by 
treatment with the demethylating agent, 5-azacytidine. Although this restored expression clearly 
indicates that 5-azacytidine can reverse the methylation status of the NDRG2 promoter, this will have 
to be confirmed by for example MSP or sequencing of the 5-azacytidine treated cells. In addition, it 
could also be relevant to investigate if the restored NDRG2 level is also reflected at protein level, 
which for example could be analyzed by western blotting of the 5-azacytidine treated cells. 
The NDRG2 promoter was also evaluated for additional regulatory mediators and it was shown that 
the MYC transcription factor was capable of binding the NDRG2 promoter in HCT116 cancer cells, 
which could indicate its involvement in the transcriptional repression of NDRG2 in cancer cells. 
Although the NDRG2 promoter was shown to be methylated, which provides the further possibility 
of repression by methyl-binding proteins, the MeCP2 was not shown to bind the methylated NDRG2 
promoter in HCT116 cancer cells. However, it was in fact not analyzed if that the cells did actually 
expressed the MeCP2 protein or confirmed that the antibody used was capable of binding MeCP2 
and therefore further experiments will be required, in order to establish if the MeCP2 is capable of 
binding to the NDRG2.  
Although the experiment conducted in this master thesis, have provided some results on how NDRG2 
may be epigenetically regulated in cancer, there is still a lot to be learned on the topic. In addition to 
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the further studies on the transcriptional repression caused by DNA methylation, it could be relevant 
to analyze the binding of the methyl-binding proteins. Since the methyl-binding proteins constitutes 
a large family, of which any in theory could bind and repress NDRG2, it should be investigated if any 
of the other methyl-binding proteins are in fact binding and participating in the observed down-
regulation of NDRG2. In addition, could any the other epigenetic modifications also be involved in 
the down-regulation of NDRG2 and it could therefore be interesting to investigate if the NDRG2 is 
also regulated by for example aberrant histone modifications, abnormal ATP-dependent chromatin 
remodeling or ncRNAs. 
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